

AD _____

Award Number: W81XWH-07-1-0234

TITLE: Ethnicity and Prostate Cancer: Vitamin D Genetic and Sociodemographic Factors

PRINCIPAL INVESTIGATOR: Kathleen C. Torkko, Ph.D.

CONTRACTING ORGANIZATION: University of Colorado Health Sciences Center
Aurora, CO 80045-0508

REPORT DATE: March 2008

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release; distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-03-08		2. REPORT TYPE Annual Summary		3. DATES COVERED (From - To) 03/01/07 – 02/28/08	
4. TITLE AND SUBTITLE Ethnicity and Prostate Cancer: Vitamin D Genetic and Sociodemographic Factors				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-07-1-0234	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Kathleen C. Torkko, Ph.D. E-Mail: kathleen.torkko@uchsc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Colorado Health Sciences Center Aurora, CO 80045				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT During the first year of the grant, one paper was accepted for publication based on the grantees PhD work. This paper would not have been completed without the additional resources provided by this grant and the grant is duly acknowledged in the paper. One other paper was published in the year as a result of collaborations with some of the grantees mentors. Both papers examined differences in genetic polymorphisms in prostate cancer by race/ethnicity in a cohort of men from south Texas. Further research is underway as a panel of new SNPs has been chosen and samples are currently being genotyped. Genotyping should be completed by mid 2008. The planned sociodemographic survey has been delayed but is currently being developed and should be completed within the next funding year. The grantees health disparities training program is going well. The grantee has taken two classes related to her work (Chronic Disease Epidemiology and Analytic Epidemiology) and is currently teaching a graduate level introductory epidemiology class with a focus on studying health disparities. She attended the "Science of Health Disparities" conference in Atlanta, GA, from November 27-30, 2007.					
15. SUBJECT TERMS Prostate cancer, health disparities, training, vitamin D receptor, genetics, sociodemographic factors, race/ethnicity					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	41	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	Page
Introduction.....	5
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusion.....	8
References.....	8
Appendices.....	9

Annual Report (Year 1 of 3): March 2008

Contract #: W81XWH-07-1-0234

Grant#: PC060447

PI: Kathleen C. Torkko, PhD, MSPH

Title: Ethnicity and Prostate Cancer: Vitamin D Genetic and Sociodemographic Factors

Introduction

The main purposes of this grant were to provide opportunities for the principle investigator to expand her PhD work and to receive training in cancer health disparity research, specifically in prostate cancer. This training program involves meeting with mentors for guidance, taking classes pertinent to her research and training objectives, and attending appropriate conferences.

Her research work is on differences in vitamin D receptor (VDR) genetic relationships to prostate cancer between non-Hispanic White (NHW) and Hispanic White (HW; mainly of Mexican origin) men in the SABOR (San Antonio Biomarkers Of Risk for prostate cancer) study run by researchers at the University of Texas Health Sciences Center, San Antonio (UTHSCSA). Hispanic men have been a focus of Dr. Torkko's PhD research for two reasons: they comprise the largest minority population in the SABOR study, and they are a largely understudied population in prostate cancer and genetic epidemiology. Understanding the relationship of genetics to prostate cancer and how this relationship varies by race/ethnicity can help elucidate racial differences seen in prostate cancer diagnosis, treatment, and survival.

This grant allows Dr. Torkko to increase the number of study participants and the number of genes and genetic polymorphisms studied to examine the effects on risk for prostate cancer by ethnicity of gene-gene interactions between the vitamin D receptor (VDR) gene and other genes in the metabolic pathway of vitamin D and testosterone.

Another objective of this proposal is to determine if sociodemographic factors differ between NHW, HW, and potentially African American men (if numbers increase) in the SABOR study and if a relationship exists between sociodemographic and genetic factors. This will be accomplished by developing and conducting a sociodemographic survey in the SABOR population.

The support provided by this Traineeship award is providing Dr. Torkko opportunities to develop as an independent prostate cancer epidemiology researcher and to further develop her areas of expertise by providing opportunities to explore differences in prostate cancer by race/ethnicity.

Body

Prostate Cancer Training Program Progress

Mentorship/Collaborations

Dr. Torkko has met with the members of her mentorship panel who have provided guidance on how to get her PhD work published and in the development of current projects. Dr. Scott Lucia, the primary mentor, an expert prostate cancer pathologist, employs Dr. Torkko as an epidemiologist/statistician in the Prostate Cancer Research Laboratory (PCRL) in the Department of Pathology at the University of Colorado Denver (UCD). Dr. Lucia has facilitated Dr. Torkko's involvement in the development of a cancer biorepository at UCD. Dr. Torkko will assist in building the patient database and developing research using available resources. This will hopefully lead to other funding opportunities. Dr. Lucia is also providing opportunities for first authorship on a paper involving research projects in the PCRL. Meetings with Dr. Lucia and other mentors have involved discussions of future projects and funding opportunities. Meetings with Dr. Robin Leach and Dr. Ian Thompson during a visit to San Antonio, TX, in April 2007, resulted in more data collection and genetic analyses that enhanced her PhD work and led to a publication on genetic differences by ethnicity in gene-gene interactions in the VDR and SRD5A2 genes [Torkko KC *et al. Clinical Cancer Research* (in press)]. Dr. Torkko also collaborated with her Texas colleagues in the publication of a paper on RNASEL variants and

their associations with prostate cancer in ethnic/racial minorities in the SABOR cohort (Shook SJ *et al.*, *Clin Cancer Res* 2007; 13;5959-64).

Scientific Conferences

As part of the training for the grant, Dr. Torkko is expected to attend scientific conferences chosen to be relevant to prostate cancer, genetic epidemiology, and/or health disparity/cultural competency. Funds have been allocated to attend at least one conference each funded year. In the 2007-08 grant period, Dr. Torkko attended the first American Association of Cancer Researchers (AACR) conference on “The Science of Cancer Health Disparities in Racial/Ethnic Minorities and Medically Underserved” in Atlanta, GA, from November 27-30, 2007. As research data become available, it is expected that abstracts will be submitted for future conferences.

Coursework

As part of the training for the grant, Dr. Torkko is expected to continue her education by taking classes on epidemiology and cultural issues. Dr. Torkko took two classes within the timeframe of the first year of the grant. In the spring semester 2007, she took the Chronic Disease Epidemiology class (PRMS 6636) offered by the Department of Preventive Medicine and Biometrics to refresh her knowledge of epidemiologic techniques. As part of the class, students were required to write a proposal using life-course methodology. Dr. Torkko wrote a proposal titled: “A Life-Course Analytical Approach for Understanding Early Exposure to Androgens and Risk for Prostate Cancer: A Case-Control Study in a Multiethnic Cohort from South Texas.” It was her aim to design a proposal that would examine exposures early in life that may explain differences in prostate cancer incidence seen between Non-Hispanic Whites and Hispanic Whites. She would like to propose this study in the SABOR cohort, but would need to procure some additional funding for this effort. The proposal is attached in the Appendix. She received an “A” in the class (see transcripts in Appendix).

In the fall semester 2007, she took an analytic epidemiology class (PRMD 7915) on survey design. She had hoped to use this class to help design the sociodemographic survey for the SABOR population. Unfortunately, the professor for the class changed the content of the class at the last moment from what was advertised to cover complex sampling designs which, although interesting, ended up having no real relationship to her research. (she received an “A” in the class). To facilitate the development of the study, she has started collaborating with a former professor who assisted with her Masters work (where she conducted a survey of Colorado primary care providers) to help design the survey to be developed and administered in the next funding year.

In the spring semester 2008, rather than taking a class, Dr. Torkko is teaching the Introductory Epidemiology class (HBSC 4001/5001) for the Health and Behavior Sciences Department at the UCD. She made health disparities a focus of the class (see course syllabus in Appendix). Often the best way to learn is to teach. She is having her students write a final project on a cancer of their choice about the epidemiology of the cancer and to identify an area where a health disparity exists. She is hoping the students will teach the teacher. Taking on this class has given Dr. Torkko invaluable experience in teaching and should lead to other teaching and career development opportunities. It has also been an important review of epidemiology for her as concepts continue to evolve since the time she took basic epidemiology classes.

Readings. Dr. Torkko is currently reading “The Spirit Catches You and You Fall Down” which she plans to discuss with her health disparities mentor, Dr. Angela Sauaia.

Research Project Progress

Sociodemographic Survey

Specific Aim #1: *Collect sociodemographic information on SABOR participants using a questionnaire and determine whether sociodemographic factors relating to prostate cancer screening, diagnosis, and treatment differ by race/ethnicity in the SABOR study. Differences in*

proportions or frequencies of sociodemographic factors will be tested by racial/ethnic group in men with prostate cancer.

Development and implementation of the survey had been delayed. Currently Dr. Torkko is collecting existing surveys and following up on contacts made during the conference in Atlanta. It is expected that a draft survey will be completed in the next month and sent to UTHSCSA for comment and approval. Their local IRB process will have to be initiated and the survey will be translated into Spanish. The whole process may take four to six months before the survey is ready to be mailed to SABOR participants.

Participation in the AACR Science of Cancer Health Disparities reinforced the importance of taking measures of SES, health status/beliefs, and other cultural issues into account when conducting and analyzing studies.

Single Nucleotide Polymorphisms

Specific Aim #2: Determine whether VDR polymorphisms, haplotypes, and gene-gene interactions differ by race/ethnicity. Men will be genotyped for VDR, CYP27B1, and CYP24 polymorphisms. A genetic association case-control study will be performed looking for associations of these polymorphisms and haplotypes with prostate cancer.

The first step of the research plan was to identify a panel of single nucleotide polymorphisms (SNPs) for the genes of interest. With the assistance of Dr. Robin Leach at UTHSCSA, a panel of 21 VDR SNPs, and 31 SNPs in vitamin D associated genes (*CYP27B1*, *CYP24A1*, *PDF*) has been assembled (see Appendix for a list of the SNPs). These SNPs were chosen as tag SNPs to identify known haplotypes in each gene. As part of her research, Dr. Leach is studying genes in the testosterone pathway and has developed an extensive panel of tagSNPs. There will be opportunities for Dr. Torkko to use these SNPs to study gene-gene interactions between vitamin D and testosterone metabolic pathway genes.

Currently, appropriate cases and controls from the SABOR study are being selected and prepared for genotyping. Unfortunately there were delays in this process due to data management issues. The database for the SABOR study had grown to the point the researchers needed to transfer management of the data to the departmental/university IT services. This has resulted in some compatibility problems that have largely been resolved. Hopefully, genotyping will be completed before the middle of 2008. Data analysis will commence as soon as data are available.

Specific Aim #3: Determine the combined relationships of sociodemographic, clinical, /pathological, and genetic factors to prostate cancer and if these relationships differ by race/ethnicity.

This aim will need to wait for completion of the previous two aims.

Key Research Accomplishments

At this point in the grant, the key accomplishments were the publication of two papers in *Clinical Cancer Research* (See Appendix). The first (Shook *et al*, *Clin Cancer Res* 2007;13:5959-64) was a collaborative effort with researchers at UTHSCSA. The second (Torkko *et al*, *Clin Cancer Res* 2008 – in press) was on the results from Dr. Torkko's PhD work. Additional genotyping needed to be performed to meet the requirements of the journal reviewers. The grant was acknowledged in the paper as it allowed time and resources to complete the work and get it published.

The main finding of the Shook paper was that in Hispanic White (HW) men and African American men with prostate cancer the odds ratios were 4.4 and 10.4, respectively, for having the *RNASEL* 462 polymorphism AA genotype compared to Non-Hispanic White men (NHW). *RNASEL* had been

previously identified as a hereditary prostate cancer susceptibility gene. This paper was the first to examine this gene in HW men.

The main finding of the Torkko paper was that the vitamin D and testosterone pathways interact to increase risk for prostate cancer in NHW and HW men, and this interaction appears to differ slightly by ethnicity. The *SRD5A2* V89L VV genotype interacts with *VDR FokI* TT/CT genotypes in NHW men and *VDR CDX2* GG genotypes in HW men to increase risk for prostate cancer

Reportable Outcomes

Other than the two papers listed in the section above for the research part of the grant, reportable outcomes that are related to the training activities of the grant and are in the Appendix. These include the proposal written for the Chronic Disease Epidemiology class, the syllabus for the Introductory Epidemiology class, and the transcript for the classes taken so far.

Conclusions

A substantial amount of work has been done for the first year of the grant, but much work still remains, particularly for the research plan. The training part of the grant has been successful in increasing knowledge and understanding of prostate cancer epidemiology and issues of health disparities in cancer. Additional classes are planned for the fall and spring semesters in the next academic year. The research portion of the grants needs to take priority for the second year to complete the genotyping and to conduct the sociodemographic survey.

References

Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. *Clin Cancer Res*. 2007;13:5959-64.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Baron A, Lucia MS, Thompson IM, and Leach RJ. *VDR* and *SRD5A2* Polymorphisms Combine to Increase Risk for Prostate Cancer in Non-Hispanic White and Hispanic White Men. *Clin Cancer Res* (Accepted for publication)

Appendices

A: Torkko et al. Clin Cancer Res Paper in Press

VDR and SRD5A2 Polymorphisms Combine to Increase Risk for Prostate Cancer in Non-Hispanic White and Hispanic White Men

Kathleen C. Torkko^{1,2}, Adrie van Bokhoven¹, Phoung Mai³, Joke Beuten³, Ivana Balic⁴, Tim E. Byers², John E. Hokanson², Jill M. Norris², Anna E. Barón², M. Scott Lucia¹, Ian M. Thompson⁵, and Robin J. Leach^{3,5,6}

¹Department of Pathology and ²Department of Preventive Medicine and Biometrics University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado; ³Department of Cellular and Structural Biology, ⁴Department of Psychiatry, ⁵Department of Urology, and ⁶Department of Pediatrics, University of Texas Health Sciences Center, San Antonio, Texas

Running title: Interaction between VDR and SRD5A2 in Prostate Cancer

Key words: prostate cancer, vitamin D receptor, SRD5A2, genetic association study, haplotypes, interaction

Corresponding Author / Reprint Requests:

Kathleen C. Torkko
University of Colorado Denver, Anschutz Medical Campus,
Department of Pathology, Mail Stop 8104,
P.O. Box 6511, Aurora, Colorado 80045
Phone: 303-724-3063
FAX: 303-724-3477
e-mail: Kathleen.torkko@uchsc.edu

Grant Support: NCI grant #5U01CA086402 from the Early Detection Research Network of the National Cancer Institute and in part by American Cancer Society grant #TURSG-03-152-01-CCE, entitled “The Role of Genetic Variation in Prostate Cancer among Hispanics and Blacks” (funding co-authors Leach, Mai, Beuten, and Balic). “Cancer Center Support Grant – P30CA46934” awarded to the University of Colorado Cancer Center via the NCI (Lead author Torkko) and a “Prostate Scholar Health Disparities Training Grant” #W81XWH-07-1-0234 from the U.S. Department of Defense (Lead author Torkko). This work was part of the research Dr. Torkko performed to meet the requirements for her PhD in epidemiology. The remaining co-authors (Thompson, Lucia, Byers, Hokanson, Norris, Baron, and van Bokhoven) provided input and scientific support as part of the committee and mentor panel for Dr. Torkko’s PhD research. No financial support was sought for their efforts.

ABSTRACT

Purpose: Vitamin D and dihydrotestosterone pathways interact to promote growth of prostatic tissue. The nuclear Vitamin D receptor (*VDR*) moderates the actions of Vitamin D. 5 α -Reductase type II (*SRD5A2*) codes for the enzyme that converts testosterone to dihydrotestosterone in the prostate. This study tested interactions of *VDR* (*CDX2*, *FokI*) and *SRD5A2* (V89L, A49T) polymorphisms and their associations with prostate cancer.

Experimental Design: This genetic association study included 932 non-Hispanic White (NHW) men and 414 Hispanic White (HW) men from south Texas. Cases had biopsy-confirmed cancer; controls had normal digital rectal exams and serum prostate specific antigen <2.5 ng/ml.

Results: Using logistic regression analyses to test associations with prostate cancer, only the V89L polymorphism (VV genotype compared to LL/LV) in HW men was statistically significant (OR=0.64; 95%CI: 0.41, 0.99). The interaction terms for *FokI* and V89L in NHW men and *CDX2* and V89L in HW men in the logistic model were significant ($p=0.02$ and 0.03 , respectively). When stratified by V89L genotype, the *FokI* polymorphism (TT/TC vs. CC) was significantly associated with prostate cancer in NHW men with the V89L VV genotype (*FokI* OR=1.53, 95%CI: 1.06, 2.23). The *CDX2* polymorphism (GG vs. AG/AA) was significantly associated with prostate cancer only in HW men with the V89L VV genotype (*CDX2* OR=3.16, 95%CI: 1.39, 7.19; interaction term $p=0.02$).

Conclusion: Our results indicate that the *SRD5A2* V89L VV genotype interacts with *VDR FokI* TT/CT genotypes in NHW men and *VDR CDX2* GG genotypes in HW men to increase risk for prostate cancer.

INTRODUCTION

Prostate cancer is the most commonly diagnosed non-skin cancer and one of the ten leading causes of death in American men.(1) The etiology of prostate cancer is not well known, although both genetic and environmental factors are believed to play a role. A twin study from Scandinavia estimated that 42% of the risk for prostate cancer might be explained by heritable factors.(2) A diverse range of foods and nutrients have been found to moderately affect risk for prostate cancer, including soy, isoflavones, milk, saturated fats, and tomato products.(3)

A link between prostate cancer and vitamin D has been hypothesized. Lower levels of vitamin D in the serum have been associated with increased prostate cancer risk.(4) *In vitro* studies have found that treating prostate cancer cells with vitamin D inhibits cell proliferation.(5) Given these observations, it has been proposed that adequate circulating levels of vitamin D are important to protect against prostate cancer.

The androgen testosterone and its bioactive form, dihydrotestosterone (DHT), are necessary for the normal growth and development of the prostate and epidemiologic evidence supports their role in the etiology of prostate cancer.(6) 5 α -reductase type II is the primary enzyme that converts testosterone to DHT in the prostate.(7) Men who lack the gene that codes for 5 α -reductase type II have low DHT levels and small prostates.(8) Finasteride, an inhibitor of 5 α -reductase type II, reduces the growth of cells from the androgen-dependent LNCaP prostate cancer cell line(9) and is associated with a decrease in tissue DHT levels.(10) The Prostate Cancer Prevention Trial (PCPT) demonstrated that men given finasteride had a 24.8% reduction in cancer prevalence over seven years compared to men given placebo.(11) Increased expression of 5 α -reductase type II is also associated with recurrent and metastatic prostate cancer implying a role for the enzyme and DHT in prostate cancer progression.(12)

Growth and differentiation of normal prostatic tissue is promoted by interactions between the vitamin D and DHT pathways.(13) Levels of the bioactive form of vitamin D, calcitriol, are controlled in an autocrine fashion to regulate cell growth and decrease the risk of the cells becoming malignant. DHT appears to act as a regulator of vitamin D activity. When cells from the prostate cancer cell line LNCaP are grown in androgen-depleted medium, vitamin D no longer inhibits cell growth. With the addition of

DHT, even at low physiologic levels (1 nM), the anti-proliferative effects of vitamin D are restored.(14) It was later demonstrated that this effect is mediated by DHT-induced suppression of 24-hydroxylase expression, the enzyme that inactivates calcitriol(15) and its precursor form.(14) Additionally, in two androgen receptor(AR)-positive prostate cancer cell lines (DHT binds to AR), AR signaling was shown to be required for the vitamin D-mediated growth inhibition of the cancer cells.(16) This sets up a paradox of androgens being associated with higher risk for cancer development, but at the same time being important for the anti-cancer activities of vitamin D.

Located on chromosome 12q13-q14, the high-affinity nuclear vitamin D receptor gene (*VDR*) mediates most of the biological activity of vitamin D.(17) If vitamin D can regulate the growth of normal and cancerous prostate cells, then variations in the activity of the *VDR* may be important in the onset and progression of prostate cancer. Two of the commonly studied *VDR* polymorphisms, *FokI* and *CDX2*, result in functional changes. The *FokI* (T/C) variant alters the translation start site resulting in two isoforms of the *VDR* protein with differing activities(18), with the protein product from the *FokI* T form exhibiting less transcriptional activation than the product from the wild-type C form.(19) The presence of the *FokI* C allele was found to affect immune cell behavior resulting in a more active immune system.(20) The *CDX2* variant in the promoter region of the *VDR* modulates promoter activity, and the *CDX2* G allele, the most common allele, shows 30% less transcriptional activity compared to the A allele.(21) Several studies of the *FokI* polymorphism and its association with prostate cancer have produced inconsistent results and a meta-analysis of several *VDR* polymorphisms concluded that *FokI* was unlikely to have a major role in prostate cancer.(22) *CDX2* has been less extensively studied but it was found to increase risk for prostate cancer in men with the heterozygous genotype and high ultraviolet B exposure.(23)

The gene that codes for 5 α -reductase type II, *SRD5A2* located on chromosome 2, has several polymorphisms that have been studied for their relationship with prostate cancer. The most common polymorphism is V89L that substitutes valine at codon 89 with leucine by a C to G nucleotide transversion. The leucine allele (L) reduces 5 α -reductase activity resulting in lower DHT levels.(24,25). The A49T polymorphism results in a threonine substitution for alanine and is associated with increased 5 α -reductase activity *in vitro* causing increased DHT production that may contribute to prostate cancer development or progression.(26) The relationship of the V89L and A49T polymorphisms with prostate cancer has not been proven conclusively. A meta-analysis of *SRD5A2* polymorphisms concluded that the V89L polymorphism likely has no, or little, relationship to prostate cancer risk and that A49T may have a modest effect accounting for only a small proportion of prostate cancer.(27)

Because of the complex etiology of prostate cancer, the effects of many individual genetic polymorphisms are likely to be small. It is possible that larger effects may only be observed when polymorphisms are considered in combination. A polygenic model incorporating multiple loci might maximize detection of individuals at high-risk for prostate cancer.(28)

The current study tested possible interactions of the *VDR* and *SRD5A2* genes as identified by two functional polymorphisms in each gene in determining risk for prostate cancer in a cohort of Non-Hispanic White and Hispanic White men from south Texas. The *a priori* hypotheses of this study were that the *FokI* T allele and the *CDX2* G allele, that both result in decreased vitamin D receptor activity, in combination with the V89L V or A49T T alleles, that result in higher levels of DHT, would lead to increased risk for prostate cancer. Although DHT is important for vitamin D activity and higher DHT levels might be hypothesized to reduce risk by increasing vitamin D levels, we believe that the less efficient vitamin D receptor as indicated by the presence of the *FokI* T and *CDX2* G alleles will not utilize the higher vitamin D levels to counter the increased risk posed by higher DHT levels.

MATERIALS AND METHODS

Study Population. Study participants came from the population-based prospective SABOR cohort study (San Antonio Biomarkers Of Risk for prostate cancer) at the University of Texas Health Sciences Center, San Antonio (UTHSCSA).(29) SABOR began enrolling men in May 2001 to examine differences in risk for prostate cancer by race/ethnicity. Three racial/ethnic groups reflecting the diversity of the southern Texas population were enrolled: non-Hispanic Whites (NHW), Hispanic Whites (HW), and African Americans. Only NHW and HW men were used in this study due to limited numbers of African American men (less than 65 prostate cancer cases). Race is self-identified and Hispanic ethnicity was assigned using the Hazuda model for the identification of Mexican Americans and other Hispanic ethnicities.(30) The Hispanic population of south Texas is approximately 95% Mexican American. All participants were consented for the genetic studies according to UTHSCSA Institutional Review Board's rules and regulations.

Cases in this analysis were men with histologically-confirmed prostate cancer in the SABOR cohort, as well as men diagnosed with confirmed prostate cancer from the same clinics and health fairs from which the SABOR cohort was recruited. Gleason scores (range 2-10) were determined from chart reviews. High-grade cancers were defined as cases with Gleason scores of seven or greater. Prostatectomy scoring was used preferentially over biopsy scores when available.

Controls, selected from the SABOR cohort, were eligible for this analysis if they had prostate-specific antigen (PSA) values less than 2.5 ng/ml at all visits (up to five annual visits) and a normal digital rectal exam (DRE) at all visits. Age, defined as age at diagnosis for the cases and age at last visit for the controls, was truncated at 45 years old and above for both cases and controls. The study population consisted of 1,346 men for a total of 585 cases and 761 controls. HW men accounted for 44% of the study sample.

Polymorphism Selection and Genotyping. Two *VDR* polymorphisms and two *SRD5A2* polymorphism were genotyped: CDX2 (rs17883968; G/A) in the *VDR* promoter region, *FokI* (rs10735810; C/T) in *VDR* exon 2, and V89L (rs523349) and A49T (rs9282858) in exon 1 of the *SRD5A2* gene.

DNA for genotyping was extracted from blood samples using a QIAamp blood kit (QIAGEN, Valencia, CA). Genotyping for CDX2, V89L, and A49T was performed with TaqMan allelic discrimination assays using the ABI 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). Originally a TaqMan assay could not be successfully designed for *FokI*. This polymorphism was genotyped using endonuclease restriction enzyme digestion. Subsequently, a *FokI* kit was developed and purchased. To do a quality control check on the original *FokI* genotyping, 324 men (19% of the sample) were re-genotyped using the TaqMan kit. There was only one discrepancy between the two methodologies for an error rate of 0.3%. Applied to our larger sample of 1,685 men this means there are potentially 5 men who are discordant. We feel this is an acceptable error rate and that the original methodology is validated. All genotyping was performed in a molecular genetics laboratory at UTHSCSA.

Men homozygous for each risk allele in the individual polymorphisms were compared to heterozygotes and homozygotes for the complimentary allele combined. Men homozygous for the *VDR* CDX2 risk allele (G) were compared to men with AG or AA genotypes. For the *SRD5A2* V89L polymorphism, the VV genotype was compared to LL and LV genotypes in all analyses. Due to a limited number of men homozygous for the risk alleles in the *VDR FokI* and *SRD5A2* A49T polymorphisms, the risk genotype was combined with the heterozygous genotype and compared to men homozygous for the complementary allele. Thus for *FokI* the comparison was between TT/CT and CC genotypes and for A49T it was between the TT/AT and AA genotypes if any TT genotypes are found.

Statistical Analyses. All analyses were stratified by ethnicity. Associations between genotypes and prostate cancer were assessed by chi-square tests (Pearson Chi-square with one or two degrees of

freedom) and logistic regression analyses. All logistic regression models included age as a continuous variable. Interactions between *VDR* and *SRD5A* polymorphisms were tested in the logistic regression analyses by adding an interaction term to the model. Nominal logistic regression was used to test the relationship of the Gleason score groups (low grade 2-6 and high grade 7-10) to controls as the referent group. Alpha levels of 0.05 were used for hypothesis testing, and 95% confidence intervals were computed for all relative risk estimates (odds ratios). For NHW men, the study sample size had 80% power ($\alpha=0.05$) to detect at least a 25% difference in proportions of genotypes between cases and controls based on published reports of genotype proportions in controls. For HW men, the detectable difference was 35%. Analyses were completed using SAS 9.1 statistical software (SAS institute, Inc., Cary, NC).

RESULTS

The study sample consisted of 932 NHW men (444 cases, 488 controls) and 414 HW men (141 cases, 273 controls; Table 1). Controls were somewhat younger than cases in both ethnic groups. Gleason score distribution was not different between ethnic groups.

Genotype distributions for the individual polymorphisms within each ethnic group did not differ by case-control status (Table 2). Genotype distributions for controls differed by ethnicity, however, for the *VDR FokI* and the *SRD5A2 V89L* polymorphisms. About 13% of NHW controls had the *FokI* TT genotype compared to 21% of HW controls ($p=0.009$). For the *V89L* polymorphism, 52% and 44% of NHW and HW controls, respectively, had the VV genotype ($p=0.001$). The genotype distributions in controls for these polymorphisms do not differ significantly from previously published results.(31,32) Additionally, *CDX2* genotype distributions in NHW controls are similar to what was found earlier.(33) There are no published data on *CDX2* for HW men.

All polymorphisms were in Hardy-Weinberg equilibrium within each ethnic group. Odds ratios and 95% confidence intervals for the hypothesized risk genotypes are presented in Table 2. The *SRD5A2 A49T* AT genotype was compared to the AA genotype as there were no homozygous TT genotypes in the sample. Only the *V89L* polymorphism in HW men was marginally significant (VV OR=0.64; 95%CI: 0.41, 0.99; $p=0.05$). No significant results were seen with the *A49T* polymorphism and, given the small numbers of men with the T allele, no interaction analyses were performed with this polymorphism.

Evidence of effect modification of the *VDR FokI* polymorphism by *SRD5A V89L* was found (logistic regression interaction term $p=0.02$). When the effect of the *FokI* polymorphism was analyzed by *V89L* genotype, the previously non-significant *FokI* effect was significant in NHW men (Table 3). In men with the *V89L* VV genotype, men with the *FokI* TT or CT genotypes were at a 50% increased risk for prostate cancer (OR=1.53; 95%CI: 1.06, 2.23; $p=0.03$). There was no evidence of interaction between *FokI* and *V89L* in HW men.

There was evidence of effect modification of the *VDR CDX2* polymorphism by *V89L* in HW men (logistic regression interaction term $p=0.03$). Men with the higher-risk *V89L* VV genotype combined with another higher-risk genotype, the *CDX2* GG genotype, to increase risk for prostate cancer. HW men with the *CDX2* GG and *V89L* VV genotypes have more than three times the risk for prostate cancer (*CDX2* GG OR=3.16; 95%CI: 1.39, 7.19; $p=0.01$; Table 4). There was no evidence of interaction in NHW men.

The individual polymorphisms were investigated for their associations with higher Gleason score, the measure of cancer grade. Gleason score is an important predictor of disease progression.(34) Decrease in differentiation as measured by the Gleason grade is related to lack of tissue function and the Gleason score correlates with overall disease-free survival: the higher the score, the more likely that disease will recur.(35) There was no evidence of associations with Gleason grade in HW men or in NHW men (results not shown).

DISCUSSION

This study is one of the few to examine genetic risks for prostate cancer in a group of Hispanic men. Using a population of Non-Hispanic White men and Hispanic White (largely Mexican American) men from South Texas, we found evidence of interaction between three functional polymorphisms from two genes in the vitamin D and androgen pathways to affect risk for prostate cancer. In NHW men there was an interaction between the *VDR FokI* and *SRD5A2 V89L* polymorphisms to increase risk in men with the *FokI* TT or CT genotypes and the V89L VV genotype. On the other hand, in HW men, the interaction for increased risk was between the *VDR CDX2 GG* and V89L VV genotypes.

This study examined two genes potentially involved with prostate cancer risk in combination. A polygenic approach may be a more appropriate method to study genetic associations with complex diseases such as cancer.(28) The association of *FokI* with colon cancer was seen only when analyzed in women with <23 CAG repeats in the androgen receptor.(36) The association with prostate cancer aggressiveness of a polymorphism in a gene that codes for an enzyme involved with the degradation of DHT, 3 beta-hydroxysteroid dehydrogenase type II, is strengthened when analyzed by *SRD5A V89L* genotype.(37)

This study found heterogeneity of effects by ethnicity. Neither *FokI* nor V89L alone was associated with prostate cancer in NHW men, but taken together, the odds for disease are increased 50% in men with the *FokI* TT/CT and V89L VV genotypes. No such association was found in HW men. HW men had more than three times the odds of prostate cancer if they had the CDX2 GG and the V89L VV genotypes. Previous studies have also observed heterogeneity of effects by ethnicity with the *FokI* polymorphism. For example, a significant trend for increasing waist-to-hip ratio with *FokI* genotype was found in Hispanic women but not in NHW women.(31)

Differences in linkage disequilibrium to unmeasured genes and/or gene-gene interactions may contribute to the differences found by ethnicity. It is possible that these differences may depend on the different combinations of these genes, or other unmeasured genes, either linked or unlinked to the *FokI*, CDX2, and V89L polymorphisms. The findings of this study suggest that associations and interactions of the *VDR* and *SRD5A* polymorphisms may be specific to ethnicity, arguing that research results should be stratified by race or ethnicity.

The association of the *SRD5A V89L* polymorphism with prostate cancer ran counter to our hypothesized effect. We hypothesized that the VV genotype would be associated with increased risk for prostate cancer compared to the LL genotype because the L allele is associated with a moderate reduction in 5 α -reductase type II activity resulting in lower DHT levels.(24) A meta-analysis of *SRD5A2* polymorphisms, however, concluded that the V89L polymorphism likely has no, or little, relationship to prostate cancer risk.(27) Most of the studies in the meta-analysis were done in NHW or African American men. Information on Hispanic men is sparse. A 2005 study in Southern California found that Hispanics with the LL genotype were at significantly increased risk from prostate cancer compared to men with the VV genotype (OR=7.3, 95%CI: 1.5,35.5), although this finding is based on only 84 cases and 44 controls of which only 2 controls had the LL genotype.(38) In the current study, HW men with the *SRD5A V89L VV* genotype had a *reduced* risk compared to the VL/LL genotypes (OR=0.64; 95%CI: 0.41, 0.99; p=0.05). There was no association with risk in NHW men. The result in HW men was marginal, however, and may reflect a more limited sample size in HW men. These findings need to be studied in a larger cohort.

In contrast to associations with prostate cancer risk, several studies found that the LL genotype was associated with increased risk for measures of disease *severity* or *progression*.(37) For example, the LL genotype was associated more aggressive disease(39), a poorer prognosis as measured by PSA failure,(40) and by the presence of metastases at the time of diagnosis.(41) Thus it appears that reduced DHT is associated with increased risk for disease *progression*.(42)

HW men in this study have a higher proportion of the LL genotype (15%) than NHW men (7%). Thus it appears that HW men are more likely to have a less efficient *SRD5A2* gene and therefore less DHT available. This could partly explain the paradox that overall HW men have lower prostate cancer rates but are more likely to have higher clinical stage at diagnosis(43), poorer survival(44), and more non-localized disease(45) than NHW men. A recent study looked at the distribution of V89L polymorphisms

in low-risk Inuit natives in Greenland compared to high-risk Swedish men. The proportion of the higher activity VV V89L genotype was significantly lower in Inuits compared to Swedish men.(46) The authors hypothesized this contributes to the lower of risk prostate cancer seen in the Inuit.

The cases in the SABOR study are largely prevalent rather than incident cases. Most men who were diagnosed during the up to five annual SABOR exams probably had already developed the disease that only became clinically evident during the increased surveillance as part of their participation in the study. Therefore, it is difficult to discern between markers that are associated with initiation or with progression of the disease. Long-term follow-up is needed to determine which cancer cases will progress. Although Gleason score is an imperfect measure of cancer progression, it can be useful to determine between the high-risk (usually Gleason score 7 and above) versus lower-risk cases. Even though no overall association with Gleason score was observed, the high-risk HW cases were more likely to have the V89L LL genotype (23%) than the low-risk cases (9%); there is no difference in NHW men (6% and 7%, respectively).

The presence of population stratification (genetic subgroups), particularly in HW men, could lead to inaccurate estimates of the genetic effects if the subgroups are not equally distributed between cases and controls. A recent study comparing admixture and substructure in Mexicans and Puerto Ricans, the two largest Hispanic/Latino subgroups in the US, found population substructure in both groups.(47) However, in their study of asthma, they found this substructure only confounded their results in Puerto Ricans and not Mexicans. The effect of population stratification may be important only if the substructure includes populations that have differential risk for the disease of interest and differential distributions of the gene of interest.(48) Mexican Americans, who comprise >90% of the SABOR sample, are primarily made up of European and Native American ancestries. Native Americans are at lower risk for prostate cancer compared to NHW men.(49) Only one of the polymorphisms in the current study has been examined in a native population, the Inuits in Greenland, where the proportion of the higher activity V89L VV genotype was significantly lower in Inuits compared to Europeans.(46) Depending on the percentage of native admixture in the SABOR Hispanic population and if there are different distributions between cases and controls, there could be an inaccurate estimate of the risk effect for the V89L polymorphism or the other polymorphisms in this study. Although a source of systematic bias has not been identified, a panel of ancestry informative markers on the SABOR population is being run to study this issue.

This study found evidence that the *SRD5A2* V89L polymorphism interacts with the functional *VDR FokI* and *CDX2* polymorphisms to affect risk for prostate cancer in Non-Hispanic and Hispanic White men, respectively. This illustrates the importance of examining multiple genes to understand genetic risks for prostate cancer and differences seen by ethnicity. Additionally, a complex analysis may be necessary to understand a complex disease. Because genome-wide linkage studies found strong locus heterogeneity of prostate cancer susceptibility genes(50), prostate cancer is not likely caused by a few genes but by multiple genes from different pathways. Therefore, a more complex analysis looking at interactions between genes rather than a single gene analysis may be necessary to understand complex diseases like prostate cancer.

ACKNOWLEDGMENTS

The participation of all study subjects in SABOR and in the prevalent prostate cancer studies at the University of Texas HSC at San Antonio is gratefully acknowledged. The study could not have been accomplished without the skilled assistance of the SABOR clinical staff. This research was supported in part by NCI grant #5U01CA086402 from the Early Detection Research Network of the National Cancer Institute and in part by American Cancer Society grant #TURSG-03-152-01-CCE, entitled “The Role of Genetic Variation in Prostate Cancer among Hispanics and Blacks.” Further support came from the “Cancer Center Support Grant – P30CA46934” awarded to the University of Colorado Cancer Center via the NCI and a “Prostate Scholar Health Disparities Training Grant” # W81XWH-07-1-0234 from the U.S. Department of Defense.

References

1. Chan JM, Jou RM, Carroll PR. The relative impact and future burden of prostate cancer in the United States. *J Urol* 2004;172:S13-6.
2. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78-85.
3. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. *Cancer* 2004;101:2371-2490.
4. Tuohimaa P, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. *Int J Cancer* 2004;108:104-8.
5. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1 α ,25-dihydroxyvitamin D₃ in seven human prostatic carcinoma cell lines. *Clin Cancer Res* 1995;1:997-1003.
6. Hsing AW, Reichardt JKV, Stanczyk FZ. Hormones and prostate cancer: current perspectives and future directions. *Prostate* 2002;52:213-35.
7. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5 α -reductase isozyme expression. *J Clin Invest* 1993;92:903-10.
8. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism, type 2. Decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. *N Engl J Med* 1974;291:944-9.
9. Bologna M, Muzi P, Biordi L, Festuccia C, Vicentini C. Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. *Urology* 1995;45:282-90.
10. Geller J. Effect of finasteride, a 5 α -reductase inhibitor on prostate tissue androgens and prostate-specific antigen. *J Clin Endocrinol Metab* 1990;71:1552-5.
11. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003;349:215-24.
12. Thomas LN, Lazier CB, Gupta R, et al. Differential alterations in 5 α -reductase type 1 and type 2 levels during development and progression of prostate cancer. *Prostate* 2004;63:231-9.
13. Leman ES, DeMiguel F, Gao AC, Getzenberg RH. Regulation of androgen and vitamin D receptors by 1,25-dihydroxyvitamin D₃ in human prostate epithelial and stromal cells. *J Urol* 2003;170:235-40.
14. Lou YR, Tuohimaa P. Androgen enhances the antiproliferative activity of Vitamin D(3) by suppressing 24-hydroxylase expression in LNCaP cells. *J Steroid Biochem Mol Biol* 2006;99:44-9.
15. Lou YR, Nazarova N, Talonpoika R, Tuohimaa P. 5 α -dihydrotestosterone inhibits 1 α ,25-dihydroxyvitamin D₃-induced expression of CYP24 in human prostate cancer cells. *Prostate* 2005;63:222-30.
16. Bao BY, Hu YC, Ting HJ, Lee YF. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. *Oncogene* 2004;23:3350-60.
17. Issa LL, Leong GM, Eisman JA. Molecular mechanism of vitamin D receptor action. *Inflamm Res* 1998;47:451-75.
18. Arai H, Miyamoto K, Taketani Y, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. *J Bone Miner Res* 1997;12:915-21.
19. Whitfield GK, Remus LS, Jurutka PW, et al. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. *Mol Cell Endocrinol* 2001;177:145-59.
20. van Etten E, Verlinden L, Giuliatti A, et al. The vitamin D receptor gene FokI polymorphism: Functional impact on the immune system. *Eur J Immunol* 2007;37:395-405.
21. Arai H, Miyamoto KI, et al. The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. *J Bone Miner Res* 2001;16:1256-64.
22. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2003;12:1395-1402.

23. Bodiwala D, Luscombe CJ, French ME, et al. Polymorphisms in the vitamin D receptor gene, ultraviolet radiation, and susceptibility to prostate cancer. *Environ Mol Mutagen* 2004;43:121-7.
24. Schatzl G, Madersbacher S, Gsur A, et al. Association of polymorphisms within androgen receptor, 5 α -reductase, and PSA genes with prostate volume, clinical parameters, and endocrine status in elderly men. *Prostate* 2002;52:130-8.
25. Makridakis NM, di Salle E., Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5 α -reductase type II. *Pharmacogenetics* 2000;10:407-13.
26. Makridakis NM, Ross RK, et al. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. *Lancet* 1999;354:975-8.
27. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. *Cancer Epidemiol Biomarkers Prev* 2003;12:618-24.
28. Latil AG, Azzouzi R, Cancel GS, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. *Cancer* 2001;92:1130-7.
29. Thompson IM, Leach R, Troyer D, et al.. Relationship of body mass index and prostate specific antigen in a population-based study. *Urol Oncol* 2004;22:127-31.
30. Hazuda HP, Comeaux PJ, Stern MP, et al.. A comparison of three indicators for identifying Mexican Americans in epidemiologic research. *Am J Epidemiol* 1986;123:96-112.
31. Sweeney C, Murtaugh MA, Baumgartner KB, et al. Insulin-like growth factor pathway polymorphisms associated with body size in Hispanic and non-Hispanic white women. *Cancer Epidemiol Biomarkers Prev* 2005;14:1802-9.
32. Zeigler-Johnson CM, Walker AH, Mancke B, et al. Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. *Hum Hered* 2002;54:13-21.
33. John EM, Schwartz GG, Koo J, Van Den BD, Ingles SA. Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer. *Cancer Res* 2005;65:5470-9.
34. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. *Am J Surg Pathol* 1996;20:286-92.
35. Narain V, Cher ML, Wood DP, Jr. Prostate cancer diagnosis, staging and survival. *Cancer Metastasis Rev* 2002;21:17-27.
36. Slattery ML, Sweeney C, Murtaugh M, et al. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. *Int J Cancer* 2006;118:3140-6.
37. Neslund-Dudas C, Bock CH, Monaghan K, et al. SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness. *Prostate* 2007;67:1654-63.
38. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5- α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. *Urol Oncol* 2005;23:246-53.
39. Cussenot O, Azzouzi AR, Nicolaiew N, et al. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5- α -reductase inhibitors. *Eur Urol* 2007;52:1082-7.
40. Shibata A, Garcia MI, Cheng I, et al. Polymorphisms in the androgen receptor and type II 5 α -reductase genes and prostate cancer prognosis. *Prostate* 2002;52:269-78.
41. Soderstrom T, Wadelius M, Andersson SO, et al. 5 α -reductase 2 polymorphisms as risk factors in prostate cancer. *Pharmacogenetics* 2002;12:307-12.
42. Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. *Ann N Y Acad Sci* 2006;1089:168-76.
43. Hoffman RM, Gilliland FD, Eley JW, et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. *J Natl Cancer Inst* 2001;93:388-95.
44. Gilliland FD, Hunt WC, Key CR. Ethnic variation in prostate cancer survival in New Mexico. *Cancer Epidemiol Biomarkers Prev* 1996;5:247-51.

45. Danley KL, Richardson JL, Bernstein L, Langholz B, Ross RK. Prostate cancer: trends in mortality and stage-specific incidence rates by racial/ethnic group in Los Angeles County, California (United States). *Cancer Causes Control* 1995;6:492-8.
46. Giwercman C, Giwercman A, Pedersen HS, et al. Polymorphisms in genes regulating androgen activity among prostate cancer low-risk Inuit men and high-risk Scandinavians. *Int J Androl* 2007; published online 03/22/07.
47. Choudhry S, Coyle NE, Tang H, et al. Population stratification confounds genetic association studies among Latinos. *Hum Genet* 2006;118:652-64.
48. Sweeney C, Wolff RK, Byers T, et al. Genetic admixture among Hispanics and candidate gene polymorphisms: potential for confounding in a breast cancer study? *Cancer Epidemiol Biomarkers Prev* 2007;16:142-50.
49. Paltoo DN, Chu KC. Patterns in cancer incidence among American Indians/Alaska Natives, United States, 1992-1999. *Public Health Rep* 2004;119:443-51.
50. Schaid DJ. The complex genetic epidemiology of prostate cancer. *Hum Mol Genet* 2004;13 Spec No 1:R103-21.

Table 1. Participant characteristics

		<u>Non-Hispanic White</u>		<u>Hispanic White</u>	
		Cases	Controls	Cases	Controls
N		444	488	141	273
Age (years)	45-59	94 (21%)	182 (37%)	43 (31%)	157 (57%)
	60-69	203 (46%)	185 (38%)	60 (42%)	95 (35%)
	70+	147 (33%)	121 (25%)	38 (27%)	21 (8%)
	Mean	66.5	64.1*	64.4	59.2*
Gleason Score	2-5	49 (15%)		10 (9%)	
	6	147 (44%)		54 (47%)	
	7	90 (27%)		33 (28%)	
	8-10	46 (14%)		19 (16%)	
	Median	6		6**	

*p<0.0001 for differences between cases and controls in both ethnic groups (T-test)

**p=0.23 for differences between NHW and HW men (Wilcoxon Rank Sum test)

Table 2. Distribution of *VDR FokI* and *CDX2* and *SRD5A2* V89L and A49T polymorphisms by case-control status in Non-Hispanic White (NHW) cases (n=439) and controls (n=488), and in Hispanic White (HW) cases (n=140) and controls (273).

Poly-morphism	Ethnicity	Geno-type	Number (%)		Chi-square p value [†]	Genotype Comparison	OR (95% CI)
			Cases	Controls			
<i>VDR CDX2</i>	NHW	GG	282 (64)	323 (66)	0.05	GG vs. AG/AA (ref)	0.87 (0.67, 1.15)
		AG	131 (29)	148 (30)			
		AA	31 (7)	17 (3)			
	HW	GG	98 (69)	174 (64)	0.32	GG vs. AG/AA (ref)	1.57 (0.99, 2.50)
		AG	38 (27)	81 (30)			
		AA	5 (4)	18 (7)			
<i>VDR FokI</i> *	NHW	TT	67 (15)	63 (13)	0.54	TT/CT vs. CC (ref)	1.12 (0.86, 1.46)
		CT	209 (47)	227 (46)			
		CC	168 (38)	198 (41)			
	HW	TT	26 (18)	57 (21)	0.73	TT/CT vs. CC (ref)	1.00 (0.68, 1.57)
		CT	70 (50)	125 (46)			
		CC	45 (32)	91 (33)			
<i>SRD5A2</i> V89L*	NHW	VV	230 (52)	251 (52)	0.93	VV vs. LV/LL (ref)	1.06 (0.82, 1.38)
		LV	185 (42)	202 (41)			
		LL	29 (6)	35 (7)			
	HW	VV	52 (37)	119 (44)	0.24	VV vs. LV/LL (ref)	0.64 (0.41, 0.99)
		LV	70 (50)	112 (41)			
		LL	19 (13)	42 (15)			
<i>SRD5A2</i> A49T	NHW	TT	0 (0)	0 (0)	0.97	AT vs. AA (ref)	1.06 (0.65, 1.75)
		AT	33 (7)	36 (7)			
		AA	411 (93)	452 (93)			
	HW	TT	0 (0)	0 (0)	0.94	AT vs. AA (ref)	1.32 (0.46, 3.73)
		AT	6 (4)	12 (4)			
		AA	135 (96)	261 (96)			

*Significant differences in genotype distributions in controls between NHW and HW men (p=0.009 for *FokI*; p=0.001 for V89L).

[†] Pearson Chi-square test with 2 d.f.

Table 3. Distribution of *VDR FokI* genotypes stratified by *SRD5A2* V89L LL/LV and VV genotype groups with age-adjusted logistic regression odds ratios (OR) and 95% confidence intervals (95%CI) for associations of *FokI* TT/CT genotypes with prostate cancer in Non-Hispanic White (NHW) and Hispanic White (HW) men.

Ethnicity	V89L Genotype	FokI Genotype	Number (%)		Chi-square p value [†]	FokI OR (95%CI)	p-value
			Cases	Controls			
NHW*	All	TT/CT	276 (62)	290 (59)	0.39	1.12 (0.86,1.46)	0.41
		CC	168 (38)	198 (41)		1.0	
	VV	TT/CT	152 (66)	142 (57)	0.03	1.53 (1.06,2.23)	0.03
		CC	78 (34)	109 (43)		1.0	
	LV/LL	TT/CT	124 (58)	148 (62)	0.33	0.79 (0.54, 1.16)	0.23
		CC	90 (42)	89 (38)		1.0	
HW**	All	TT/CT	96 (68)	182 (67)	0.77	1.00 (0.63, 1.57)	0.99
		CC	45 (32)	91 (33)		1.0	
	VV	TT/CT	40 (77)	83 (70)	0.34	1.43 (0.66, 3.13)	0.36
		CC	12 (23)	36 (30)		1.0	
	LV/LL	TT/CT	56 (63)	99 (64)	0.83	0.86 (0.49, 1.54)	0.62
		CC	33 (37)	55 (36)		1.0	

*Interaction term in full logistic regression model for *FokI*-V89L p=0.02

**Interaction term in full logistic regression model for *FokI*-V89L p=0.32

[†] Pearson Chi-square with 1 d.f.

Table 4. Distribution of VDR CDX2 genotypes stratified by SRD5A2 V89L LL/LV and VV genotype groups with age-adjusted logistic regression odds ratios (OR) and 95% confidence intervals (95%CI) for associations of CDX2 GG genotype with prostate cancer in Non-Hispanic White (NHW) and Hispanic White (HW) men.

Ethnicity	V89L Genotype	CDX2 Genotype	Number (%)		Chi-square p value [†]	CDX2 OR (95%CI)	p-value
			Cases	Controls			
NHW*	All	GG	282 (64)	323 (66)	0.39	0.87 (0.67, 1.14) 1.0	0.34
		AG/AA	162 (36)	165 (34)			
	VV	GG	140 (61)	164 (65)	0.31	0.82 (0.57, 1.20) 1.0	0.31
		AG/AA	90 (39)	87 (35)			
	LV/LL	GG	142 (66)	159 (67)	0.87	0.93 (0.63, 1.39) 1.0	0.74
		AG/AA	72 (34)	78 (33)			
HW**	All	GG	98 (69)	174 (64)	0.24	1.57 (0.99, 2.50) 1.0	0.05
		AG/AA	43 (31)	99 (36)			
	VV	GG	42 (81)	74 (62)	0.02	3.16 (1.39, 7.19) 1.0	0.01
		AG/AA	10 (19)	45 (38)			
	LV/LL	GG	56 (63)	100 (65)	0.75	1.13 (0.63, 2.02) 1.0	0.68
		AG/AA	33 (37)	54 (35)			

*Interaction term in full logistic regression model for CDX2-V89L p=0.63

**Interaction term in full logistic regression model for CDX2-V89L p=0.03

[†] Pearson Chi-square with 1 d.f.

Appendices – cont.

B: Shook *et al Clin Cancer Res* paper

Association of RNASEL Variants with Prostate Cancer Risk in Hispanic Caucasians and African Americans

Stacie J. Shook,¹ Joke Beuten,¹ Kathleen C. Torkko,⁵ Teresa L. Johnson-Pais,²
Dean A. Troyer,³ Ian M. Thompson,⁴ and Robin J. Leach^{1,2,4}

Abstract Purpose: The *RNASEL* gene at 1q25 has been identified as a hereditary prostate cancer susceptibility gene, but to date, no study has investigated the role of *RNASEL* variants in Hispanic Caucasian men with prostate cancer.

Experimental Design: Two *RNASEL* common variants, located at amino acids 462 and 541, were genotyped in non-Hispanic Caucasian, Hispanic Caucasian, and African American prostate cancer cases and controls.

Results: The *RNASEL* 462 AA genotype was found to increase prostate cancer risk over 4-fold in Hispanic Caucasians [odds ratio (OR), 4.43; 95% confidence interval (95% CI), 1.68-11.68; $P = 0.003$] and over 10-fold in African Americans (OR, 10.41; 95% CI, 2.62-41.40; $P = 0.001$) when compared with the GG genotype. Analysis of the *RNASEL* 541 variant showed that Hispanic Caucasian patients with the GG genotype had a statistically significant increase in their risk for developing prostate cancer when compared with the TT and GT genotypes (OR, 1.91; 95% CI, 1.16-3.14; $P = 0.01$). A common G-T haplotype for the combination of the *RNASEL* 462 and 541 variants was found to occur more frequently in controls compared with cases in African Americans ($P = 0.04$) but not in non-Hispanic Caucasians or Hispanic Caucasians.

Conclusions: This is the first study that investigates the association of prostate cancer risk with *RNASEL* variants in Hispanic men. Our data support the role of *RNASEL* as a predisposition gene for prostate cancer and showed a significant association between the *RNASEL* 462 variant and prostate cancer risk in African Americans and Hispanic Caucasians.

Over 218,000 men in the United States are estimated to be diagnosed with prostate cancer (MIM 176807) in 2007 alone and approximately 27,000 men will die from it (1). Although prostate cancer is the most common non-skin cancer and the second leading cause of cancer death in men in the United States, little is known about inherited factors that influence its genetic predisposition. Many factors are known to contribute to the risk of prostate cancer, including diet, race and ethnicity, age, sexual history, and family history (2–6).

Currently, elevated serum levels of prostate-specific antigen and/or an abnormal digital rectal exam are the main methods

for diagnosing this disease (7). However, there is increased impetus for better understanding of the molecular processes involved in prostate carcinogenesis with the ultimate goal of discovering new biomarkers, which may be beneficial in the detection, prevention, and/or treatment of this disease (8). Only limited association studies on candidate genes and/or linkage analyses for susceptibility loci have consistently produced positive findings. In 1996, the first prostate cancer susceptibility locus, the *hereditary prostate cancer (HPC) 1* locus (*HPC1*; MIM 601518), was mapped to chromosomal region 1q24-q25 by linkage analysis (9) and since this initial report, several prostate cancer susceptibility loci have been identified (10–18). Because the majority of these regions have not been consistently confirmed in independent populations, evidence has emerged that prostate cancer is a genetically complex and heterogeneous disorder, with multiple genetic and environmental factors contributing to the disease.

There is substantial evidence for a genetic component in the vulnerability to prostate cancer. A cohort study of twins reported by Lichtenstein et al. (19) indicated that the proportion of prostate cancer risk accounted for by heritable factors is estimated to be 42%. Prostate cancer is classified as hereditary (HPC) or sporadic and it is assumed that HPC might be caused by rare, highly penetrant alleles at single gene forms of the disease (20). Alternatively, the sporadic prostate cancer cases may involve some of the same genes and pathways that determine HPC incidence, but they most likely involve more common, low- to moderate-penetrant alleles in genes that are components of pathways that influence prostate function (21–23).

Authors' Affiliations: Departments of ¹Cellular and Structural Biology, ²Pediatrics, ³Pathology, and ⁴Urology, The University of Texas Health Science Center, San Antonio, Texas and ⁵Departments of Pathology and Preventive Medicine and Biometrics, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado

Received 3/27/07; revised 6/6/07; accepted 7/11/07.

Grant support: American Cancer Society grant TURSG-03-152-01-CCE, entitled "The Role of Genetic Variation in Prostate Cancer among Hispanics and Blacks," NCI grant 5U01CA086402 from the Early Detection Research Network of the National Cancer Institute, and San Antonio Cancer Institute grant P30 CA54174.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Robin J. Leach, Department of Cellular and Structural Biology, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900. Phone: 210-567-6947; Fax: 210-567-6781; E-mail: leach@uthscsa.edu.

© 2007 American Association for Cancer Research.

doi:10.1158/1078-0432.CCR-07-0702

An important gene involved in innate immunity and apoptosis is the gene encoding 2'-5'-oligoadenylate (2-5A)-dependent RNASEL (*RNASEL*; MIM 180435). *RNASEL*, located at 1q25, regulates cell proliferation and apoptosis through the IFN-regulated 2-5A pathway (24) that mediates antiviral and antiproliferative activities (25–27) and has been suggested to be a candidate tumor suppressor gene. Previous studies indicated that germ-line mutations in the *RNASEL* gene segregate in prostate cancer families that show linkage to the HPC1 region (28). The investigators also found a truncating mutation (E265X) and an initiation-codon mutation (M11) segregating with the disease in two HPC1-linked families. Functional studies show that both mutations were associated with a reduction in *RNASEL* activity (28). Furthermore, loss of the wild-type *RNASEL* allele was found in tumor tissue from an affected patient in a family with the E265X mutation, accompanied by absent protein expression. This E265X mutation was also associated with HPC in Finnish patients (29). Follow-up studies revealed a frameshift mutation, 471delAAAG, as a founder allele in Ashkenazi Jews (30).

There are numerous nucleotide variants identified in the *RNASEL* gene, with seven of them resulting in protein sequence changes (29). Six variants cause missense alterations and one rare variant creates a nonsense mutation. The two most commonly found variants in the U.S. non-Hispanic Caucasian population are the nonsynonymous variants: Arg⁴⁶²Gln (G→A) and Asp⁵⁴¹Glu (T→G). The Arg⁴⁶²Gln variant reduces the ability of the cell to cause apoptosis in response to activation by 2-5 (A) and also has three times less enzymatic activity than normal (31), whereas the Asp⁵⁴¹Glu variant has no known effect on *RNASEL* protein function (32). There continues to be much debate over whether these common variants increase the risk of prostate cancer. The Arg⁴⁶²Gln AA genotype has been associated with both increased prostate cancer in U.S. Caucasian sample groups (31, 32) and decreased prostate cancer risk in Caucasian and Japanese sample groups (33, 34). Previous studies using the Asp⁵⁴¹Glu variant within *RNASEL* indicated that the GG and TT genotypes were associated with an increased risk for prostate cancer in Japanese (34) and European-American samples, respectively (17). On the other hand, a significant negative association of the TT genotype with prostate cancer in Swedish Caucasian samples was reported by Wiklund et al. (35).

In summary, several studies provide strong support, both functional and epidemiologic, that *RNASEL* plays a role in HPC, yet other studies have suggested that its role may be small. To date, no association study has been done using Hispanic Caucasian prostate cancer cases. Furthermore, no significant association has been reported in African American prostate cancer cases thus far. In this study, we analyzed an extended group of samples from three different racial/ethnic groups to determine whether a significant association exists between the allelic variants *RNASEL* 462 and/or *RNASEL* 541 and prostate cancer in non-Hispanic Caucasians, Hispanic Caucasians, and/or African Americans.

Materials and Methods

Study participants. The San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort was used for the study. The San Antonio Center for Biomarkers of Risk of Prostate Cancer is funded by the

National Cancer Institute and has been prospectively enrolling healthy male volunteers for over 6 years. Digital rectal exams were done and serum prostate-specific antigen levels were determined at every annual visit. Cases were individuals with a known history of prostate cancer enrolled in a parallel study of prevalent prostate cancer or individuals enrolled in the San Antonio Center for Biomarkers of Risk of Prostate Cancer Study who were diagnosed with prostate cancer. Cases had biopsy-confirmed prostate cancer and controls consisted of male volunteers of at least 45 years old who had normal digital rectal exams and prostate-specific antigen levels of <2.5 ng/mL on at least two and up to six study visits. Race/ethnicity was self-reported. Table 1 shows the characteristics of the study samples. For this study, we used 933 non-Hispanic Caucasians (430 cases and 503 controls), 392 Hispanic Caucasians (150 cases and 242 controls), and 214 African Americans (68 cases and 146 controls). This study received Institutional Review Board approval from the University of Texas Health Science Center at San Antonio. Informed consent was obtained from all subjects.

DNA isolation and genotyping. DNA was isolated from participants' whole blood cells using a QIAamp DNA Blood Maxi kit (Qiagen) and was used for genotyping. The Taqman allelic discrimination assay (Applied Biosystems) was used to genotype the nucleotide variants *RNASEL* Arg⁴⁶²Gln (rs486907) and Asp⁵⁴¹Glu (rs627928). Primers and probes were designed using Primer Express (Applied Biosystems). The primers and probes for Arg⁴⁶²Gln were as follows: forward primer 5'-GGAAGATGTGGAAATGAGGAAGA-3', reverse primer 5'-TGCA-GATCCTGGTGGGTGTA-3', and probes 5'-VICCAGGACATTTCGGG-CAA-MGB and 5'-FAMCAGGACATTTTGGGCAA-MGB. The primers and probes for Asp⁵⁴¹Glu were as follows: forward primer 5'-TCTATGTGGTAAAGAAGGGAAGCA-3', reverse primer 5'-TTGAAC-CACCTCTTCATTACTTTGAG-3', and probes 5'-VICTTTCAGATCCT-CAAAT-MGB and 5'-FAMTTTCAGCTCCTCAAAT-MGB. The target sequences were amplified by PCR in 7 μ L reaction mix containing

Table 1. Characteristics of subjects for this study

Subgroup	Cases (n = 732)	Controls (n = 1,546)
	n (%)	n (%)
Ethnic background		
Non-Hispanic Caucasian	503 (68.7)	840 (54.3)
Hispanic Caucasian	159 (21.7)	501 (32.4)
African American	70 (9.6)	205 (13.3)
Age (y)		
≤50	21 (2.9)	214 (13.8)
51-60	165 (22.5)	601 (38.9)
61-70	329 (45.0)	485 (31.4)
>70	217 (29.6)	246 (15.9)
PSA (ng/mL)		
≤4.0	138	1,546
4.1-10.0	30	0
10.1-20.0	2	0
>20.0	4	0
Mean (SD)	3.284 (4.21)	0.895 (0.461)
DRE		
Normal	47	1,546
Abnormal	113	0
Family history of PCa		
Negative	531 (72.5)	1,260 (81.5)
Positive	201 (27.5)	286 (18.5)
Gleason score	n = 560	
<7	326 (58.2)	
7	153 (27.3)	
>7	81 (14.5)	

Abbreviations: PSA, prostate-specific antigen; DRE, digital rectal exam; PCa, prostate cancer; SD, standard deviation.

Table 2. Allele frequencies for the more common allele by race/ethnicity and case-control status

SNP	NCBI reported CEU	NCBI reported YRI	Non-Hispanic Caucasians			Hispanic Caucasians			African Americans		
			Cases (n = 430)	Controls (n = 503)	P	Cases (n = 150)	Controls (n = 242)	P	Cases (n = 68)	Controls (n = 146)	P
RNASEL 462 G	0.592	0.942	0.649	0.663	0.90	0.687	0.766	0.01	0.754	0.874	0.0005
RNASEL 541 G	0.625	0.217	0.545	0.560	0.66						
RNASEL 541 T						0.493	0.529	0.33	0.657	0.689	0.52

Abbreviations: NCBI, National Center for Biotechnology Information; CEU, CEPH (Utah residents with ancestry from northern and western Europe); YRI, Yoruba in Ibadan, Nigeria.

10 ng of genomic DNA, 900 nmol/L of each primer, 200 nmol/L of each probe, and 1× Taqman Universal PCR Master Mix (Applied Biosystems). PCRs were incubated at 95°C for 10 min followed by 40 cycles of denaturing at 95°C for 15 s and annealing/extending at 60°C for 1 min. Genotypes were determined using an ABI 7900HT Sequence Detection System (Applied Biosystems) and analyzed with the SDS 2.0 software (Applied Biosystems). To ensure the quality of the genotyping, consistent results were required for eight control samples added to each 384-well reaction plate. We also repeated ~15% of the control samples to check for error rates and found a 100% concordance rate for the genotyping results of RNASEL 462 and one mismatch for marker RNASEL 541. Both markers were in Hardy-Weinberg equilibrium in the control samples ($P > 0.05$).

Statistics. For each single nucleotide polymorphism (SNP), allele frequency was determined for the three ethnic groups individually and the frequencies among the ethnic sample groups were compared using the χ^2 test. The Hardy-Weinberg equilibrium test was done on the control population for both SNPs. To estimate the association between prostate cancer risk and each RNASEL SNP, age-adjusted odds ratios (OR) and 95% confidence intervals (95% CI) were determined using logistic regression models. For the purpose of these calculations, study age among controls was the age at last follow-up, whereas age among cases was the age at cancer diagnosis. All analyses were done using SAS statistical software version 9.1 (SAS Institute) and stratified by ethnicity. All statistical tests were two sided and significance was set at $P < 0.05$. Haplotypes and measures of linkage disequilibrium between the two markers were determined using Haploview version 3.2⁶ (36) for each race/ethnicity.

Results

Allele frequencies. We determined the allelic frequency for the Arg⁴⁶²Gln and Asp⁵⁴¹Glu SNPs from 1,539 individuals (648 cases and 891 controls) enrolled in the San Antonio Center for Biomarkers of Risk of Prostate Cancer cohort, including 933 non-Hispanic Caucasian men (503 controls and 430 cases), 392 Hispanic Caucasian men (242 controls and 150 cases), and 214 African American men (146 controls and 68 cases; Table 2). Allelic frequencies for the Arg⁴⁶²Gln SNP are significantly different among the Hispanic Caucasians and African Americans ($P = 0.01$ and 0.0005 , respectively; Table 2). The G allele was the most common allele found for the Arg⁴⁶²Gln SNP across all ethnic/racial groups. Conversely, the G allele of the Asp⁵⁴¹Glu SNP was more prevalent among the non-Hispanic Caucasian men, whereas the T allele was more common among Hispanic Caucasian men and African American men (Table 2).

Our control population was, on average, younger than our prostate cancer cases ($P < 0.0001$). Mean age (SD) for the control group was 61.8 (8.9) years, whereas mean age (SD) for our cases was 65.5 (8.3) years (Table 1). Because of this difference across our two groups and the fact that prostate cancer risk increases with age, all the ORs were adjusted for age. The markers were determined to be in Hardy-Weinberg equilibrium in the control population.

Associations of RNASEL 462 and 541 SNPs with prostate cancer risk. Age-adjusted logistic regression analysis stratified by ethnicity showed a statistically significant association between the AA genotype of Arg⁴⁶²Gln and prostate cancer risk in Hispanic Caucasian men, with a >4-fold increase in prostate cancer risk (OR, 4.43; 95% CI, 1.68-11.68; $P = 0.003$) compared with the GG genotype (Table 3). Furthermore, a >10-fold increase in prostate cancer risk was observed for the AA genotype at Arg⁴⁶²Gln in the African American samples (OR, 10.41; 95% CI, 2.62-41.40; $P = 0.001$; Table 3). In the non-Hispanic Caucasian men, however, no significant association for the Arg⁴⁶²Gln variant could be found. Assuming a recessive model, age-adjusted ORs for the presence of the AA genotype in the RNASEL 462 SNP, compared with GG and AG genotypes, showed that the observed risk estimate is slightly decreased in both sample groups (OR, 4.03; 95% CI, 1.56-10.42 in Hispanic Caucasian men, $P = 0.004$; OR, 9.84; 95% CI, 2.51-38.54 in African American men, $P = 0.001$; Table 3). In the African American men, we also noticed a significant result under the dominant model (AA/AG versus GG genotypes), with a 2-fold increase in risk estimate (OR, 2.07; 95% CI, 1.06-4.05; $P = 0.03$; Table 3).

Association analysis of the RNASEL 541 SNP with prostate cancer in age-adjusted samples from the three different ethnic groups revealed that under the assumption of a recessive model, Hispanic Caucasian men with a GG genotype showed a slightly higher risk for prostate cancer (OR, 1.91; 95% CI, 1.16-3.14; $P = 0.01$; Table 4). No significant association was found in the non-Hispanic Caucasian or African American men for this variant.

The effect of the 462 variant on prostate cancer was calculated using the population attributable fraction where population attributable fraction = $F(RR - 1) / RR$ in which F equals the proportion of cases with mutated allele (0.313 for Hispanic Caucasians and 0.246 for African Americans) and RR equals the relative risk (estimated here with the conservative OR of 1.5; ref. 37). This gives a population attributable fraction of 0.10 for Hispanic Caucasians and of 0.08 for African Americans, indicating that the mutated allele of the 462 variant

⁶ <http://www.broad.mit.edu/mpg/haploview/>

Table 3. Age-adjusted ORs for RNASEL 462 SNP and prostate cancer risk

	Genotype	Cases, n (%)	Controls, n (%)	OR (95% CI)	P
Non-Hispanic Caucasians		n = 430	n = 503		
	GG	187 (43.5)	221 (44)	1.0 (Reference)	
	AG	183 (42.5)	225 (45)	0.98 (0.74-1.30)	0.89
	AA	60 (14)	57 (11)	1.30 (0.86-1.98)	0.21
	AA vs AG/GG (Rec A)			1.32 (0.89-1.95)	0.17
Hispanic Caucasians		n = 150	n = 239		
	GG	72 (48)	136 (57)	1.0 (Reference)	
	AG	62 (41)	96 (40)	1.24 (0.79-1.93)	0.35
	AA	16 (11)	7 (3)	4.43 (1.68-11.68)	0.003
	AA vs AG/GG (Rec A)			4.03 (1.56-10.42)	0.004
African Americans		n = 68	n = 145		
	GG	45 (66)	111 (77)	1.0 (Reference)	
	AG	13 (19)	31 (21)	1.26 (0.58-2.73)	0.56
	AA	10 (15)	3 (2)	10.41 (2.62-41.40)	0.001
	AA vs AG/GG (Rec A)			9.84 (2.51-38.54)	0.001
	AA/AG vs GG (Dom A)			2.07 (1.06-4.05)	0.03

Abbreviations: Rec, recessive; Dom, dominant.

is implicated in 10% of the Hispanic Caucasian prostate cancer cases and 8% of the African American prostate cancer cases that we studied. The population attributable fraction or effect of the 541 variant on prostate cancer indicates that the mutated allele is implicated in 17% of Hispanic Caucasian prostate cancer cases of our study group.

Haplotype analysis of RNASEL 462 and 541 SNPs with prostate cancer risk. There was high linkage disequilibrium between the two polymorphisms in the three ethnic/racial sample groups with D-prime values >0.90 in both the Hispanic Caucasians and non-Hispanic Caucasians, indicating that both SNPs are in nearly complete linkage disequilibrium in these sample groups. The D-prime value in the African Americans was 0.79. In the non-Hispanic Caucasians, both SNPs are part of a haplotype block as defined by the Haploview program with the option of adopting block definition proposed by Gabriel et al. (38). A common G-T haplotype for the RNASEL 462 and

541 SNP combination was found to occur more frequently in controls compared with cases in African Americans (controls, 0.686; cases, 0.586; $P = 0.04$) but not in non-Hispanic Caucasians (controls, 0.444; cases, 0.448; $P = 0.87$) or in Hispanic Caucasians (control, 0.526; cases, 0.464; $P = 0.08$; Table 5).

Discussion

Linkage analyses of high-risk prostate cancer families provide convincing evidence that the *HPC1* locus is likely to harbor a prostate cancer susceptibility gene (9). *RNASEL* has been proposed as the putative tumor suppressor gene for this region through a positional cloning and candidate gene approach (28). Association analysis of two variants within *RNASEL* (Arg⁴⁶²Gln and Asp⁵⁴¹Glu) indicated that the results are controversial, and several of the studies have failed to reveal

Table 4. Age-adjusted ORs for RNASEL 541 SNP and prostate cancer risk

	Genotype	Cases, n (%)	Controls, n (%)	OR (95% CI)	P
Non-Hispanic Caucasians		n = 430	n = 484		
	TT	100 (23)	91 (19)	1.0 (Reference)	
	GT	190 (44)	254 (52)	0.71 (0.51-1.01)	0.06
	GG	140 (33)	139 (29)	0.95 (0.66-1.38)	0.80
	GG vs GT/TT (Rec G)			1.21 (0.91-1.60)	0.20
Hispanic Caucasians		n = 150	n = 242		
	TT	41 (27)	69 (28)	1.0 (Reference)	
	GT	66 (44)	125 (52)	0.88 (0.53-1.47)	0.63
	GG	43 (29)	48 (20)	1.76 (0.98-3.19)	0.06
	GG vs GT/TT (Rec G)			1.91 (1.16-3.14)	0.01
African Americans		n = 68	n = 146		
	TT	31 (46)	71 (49)	1.0 (Reference)	
	GT	28 (41)	60 (41)	1.02 (0.54-1.94)	0.94
	GG	9 (13)	15 (10)	1.69 (0.65-4.41)	0.29
	GG vs GT/TT (Rec G)			1.67 (0.67-4.16)	0.27
	GG/GT vs TT (Dom G)			1.14 (0.63-2.07)	0.66

Table 5. Estimated frequencies for common haplotypes

	Non-Hispanic Caucasians			Hispanic Caucasians			African Americans		
	Cases (n = 430)	Controls (n = 503)	P	Cases (n = 150)	Controls (n = 242)	P	Cases (n = 68)	Controls (n = 146)	P
RNASEL 462-541									
G-T	0.448	0.444	0.87	0.464	0.526	0.08	0.586	0.686	0.04
A-G	0.344	0.346	0.93	0.284	0.232	0.10	0.168	0.197	0.47
G-G	0.201	0.209	0.69	0.223	0.239	0.60	0.175	0.114	0.08

an association. The Arg⁴⁶²Gln AA genotype has been associated with both increased prostate cancer in U.S. Caucasian sample groups (31, 32) as well as decreased prostate cancer risk in Caucasian and Japanese sample groups (33, 34). These findings were in contrast to other studies concluding that the 462 variant was not associated with prostate cancer disease risk in different sample groups including Caucasians from the United States, Sweden, or Germany and Japanese samples (17, 29, 35, 39). The reported results might be conflicting given potential genetic differences in prostate cancer across ethnic and racial groups (5, 6). Other possible explanations for the observed differences might be the manner in which controls were selected for these studies and/or the lack of power to detect association due to small sample sizes.

Previous studies using the Asp⁵⁴¹Glu variant within RNASEL indicated that the GG genotype was associated with an increased risk for prostate cancer in a Japanese study (34). On the other hand, a study in European-American samples resulted in a significant positive association of the TT genotype with prostate cancer (17) and in a significant negative association of the TT genotype with prostate cancer in Swedish Caucasian samples (35). No association for the Asp⁵⁴¹Glu variant was found in several other studies (29, 31, 33, 39). Furthermore, no study reported to date has examined/confirmed the role of RNASEL variants in the Hispanic Caucasian or African American population.

To test the hypothesis that RNASEL sequence variants are associated with prostate cancer risk, we did a case-control genotype analysis on two common variants of RNASEL in more than 1,500 men from the South Texas region including 933 non-Hispanic Caucasians, 214 African Americans, and 392 Hispanic Caucasians. We included African Americans and Hispanic Caucasians in the analysis because these ethnic study groups are of particular interest; African Americans have the highest risk and death rate, whereas Hispanics are the fastest growing minority population in the United States. The two RNASEL variants analyzed in this study have not been extensively evaluated in African American populations and have not been studied at all in Hispanic Caucasian populations.

The allelic frequencies for Arg⁴⁶²Gln are significantly different among the Hispanic Caucasians and African Americans. This suggests an ethnic-specific allele distribution and is a likely explanation why substantial differences in the incidence of prostate cancer are observed among populations.

The most significant finding was the association of the Arg⁴⁶²Gln genotype with increased prostate cancer risk in both the Hispanic Caucasian and African American samples. Age-adjusted ORs for Arg/Gln (AG) and Gln/Gln (GG) genotypes, compared with Arg/Arg (AA), showed that the Arg/Arg (AA) genotype increases prostate cancer risk over 4-fold in Hispanic

Caucasians and over 10-fold in African Americans, which suggests a recessive model for the RNASEL 462 AA genotype. This is to our knowledge the first report on the significant association of Arg⁴⁶²Gln genotypes with increased prostate cancer risk in Hispanic Caucasian or African American men. Our results support the findings of Casey et al. (31) and Xiang et al. (32) showing that the AA genotype of the Gln462 variant is significantly associated with prostate cancer, although they differ from the findings of Casey et al. (31) in that we found the association in Hispanic Caucasians and African Americans but not in non-Hispanic Caucasians. Our results suggest that the role of the Arg⁴⁶²Gln variant in the development of prostate cancer is different across populations. From our sample group, we conclude that the genetic influence of the Arg⁴⁶²Gln variant within RNASEL on prostate cancer in the non-Hispanic Caucasian samples is relatively small, if there is any effect at all. Because it has been shown that the Gln462 AA genotype has three times less enzymatic activity than the wild-type protein (31), our data support the hypothesis that the less active RNASEL protein could leave viral infections intact, leading to inflammation, which eventually could lead to prostate cancer. Additional functional evidence for this variant's role in prostate cancer development comes from the observation that the Arg⁴⁶²Gln variant reduced the ability of RNASEL to cause apoptosis in response to activation by 2-5A (32) and suppresses antiviral effects of IFN (25–27). Furthermore, a strong association between infection with the xenotropic MuLV-related (XMRV) virus and homozygous mutant (Gln462 AA genotype) cases has been reported by Urisman et al. (40), which implicates that defects in RNASEL activity may lead to persistent viral infection *in vivo*.

Analysis of the RNASEL Asp⁵⁴¹Glu variant in the three racial/ethnic groups revealed a statistically significant increase in the risk for developing prostate cancer for the RNASEL 541 Glu/Glu (GG) genotype versus the combined Asp/Asp and Asp/Glu genotypes in the Hispanic Caucasian samples. An association of the GG genotype at RNASEL 541 with a slightly increased prostate cancer risk was also reported by Noonan-Wheeler et al. (17) among Caucasian individuals. However, we observed the finding in the Hispanic Caucasian group, whereas non-Hispanic Caucasians did not show a significant positive association for the GG genotype. Our data suggest that susceptibility to develop prostate cancer at this variant is likely ethnic specific and that the RNASEL Asp⁵⁴¹Glu variant does not seem to have a major effect on the development of prostate cancer in our non-Hispanic Caucasian or African-American population, whereas it seems to play a role in the Hispanic Caucasian cancer cases. Alternatively, because the Asp⁵⁴¹Glu variant had similar enzymatic activity as wild-type RNASEL (32), the substitution of the amino acid Glu by Asp might not

be of any functional significance and it is therefore possible that the RNASEL 541 variant may be in linkage disequilibrium with a nearby functional polymorphism(s) within the *RNASEL* gene or within another gene nearby such that the actual causal variant(s) resides on diverse haplotypes in different study populations. Therefore, additional studies are needed to confirm and clarify the functional significance of these findings in the vulnerability/etiology of prostate cancer.

A common G-T haplotype for the combination of the RNASEL 462 and 541 variants was found to occur more frequently in controls compared with cases in African Americans but not in non-Hispanic Caucasians or in Hispanic Caucasians. These findings are consistent with the observation of Wiklund et al. (35) who found that in sporadic cancer cases, the frequency of the haplotype significantly associated with prostate cancer risk (containing the G-T alleles for RNASEL

462 and 541, respectively) also occurred at higher frequencies among controls compared with sporadic prostate cancer cases.

In conclusion, we confirm the likely involvement of RNASEL in the etiology of prostate cancer and we further provide the first evidence for an association of the *RNASEL* gene with prostate cancer in Hispanic Caucasian and African American men. The prostate cancer risk differs widely between racial/ethnic groups, indicating that race/ethnicity plays a role in the development of prostate cancer. This is likely because each individual brings with them genetic material that sets each race and ethnicity apart. Furthermore, there may be different exposures to environmental factors between the populations. Involvement of environmental factors combined with genetic background may result in the differences in incidence of prostate cancer observed in these populations.

References

1. American Cancer Society. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
2. Kolonel LN. Fat, meat, and prostate cancer. *Epidemiol Rev* 2001;23:72–81.
3. Chan JM, Giovannucci EL. Dairy products, calcium, and vitamin D and risk of prostate cancer. *Epidemiol Rev* 2001;23:87–92.
4. Hayes RB, Pottern LM, Strickler H, et al. Sexual behaviour, STDs, and risks for prostate cancer. *Br J Cancer* 2000;82:718–25.
5. Merrill RM, Lyon JL. Explaining the difference in prostate cancer mortality rates between white and black men in the United States. *Urology* 2000;55:730–5.
6. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moynour C. Association of African-American ethnic background with survival in men with metastatic prostate cancer. *J Natl Cancer Inst* 2001;93:219–25.
7. Hernandez J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. *Cancer* 2004;101:894–904.
8. Hernandez J, Balic I, Johnson-Pais TL, et al. Association between an estrogen receptor α gene polymorphism and the risk of prostate cancer in black men. *J Urol* 2006;175:523–7.
9. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. *Science* 1996;274:1371–4.
10. Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2–43. *Am J Hum Genet* 1998;62:1416–24.
11. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. *Am J Hum Genet* 1999;64:776–87.
12. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. *Nat Genet* 1998;20:175–9.
13. Berry R, Schroeder JJ, French AJ, et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. *Am J Hum Genet* 2000;67:82–91.
14. Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. *Nat Genet* 2001;27:172–80.
15. Suarez BK, Lin J, Burmester JK, et al. A genome screen of multiplex sibships with prostate cancer. *Am J Hum Genet* 2000;66:933–44.
16. Neuhausen SL, Farnham JM, Kort E, Tavtigian SV, Skolnick MH, Cannon-Albright LA. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. *Hum Mol Genet* 1999;8:2437–42.
17. Noonan-Wheeler FC, Wu W, Roehl KA, et al. Association of hereditary prostate cancer gene polymorphic variants with sporadic aggressive prostate carcinoma. *Prostate* 2006;66:49–56.
18. Wiklund F, Gillanders EM, Albertus JA, et al. Genome-wide scan of Swedish families with hereditary prostate cancer: suggestive evidence of linkage at 5q11.2 and 19p13.3. *Prostate* 2003;57:290–7.
19. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78–85.
20. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. *Proc Natl Acad Sci U S A* 1992;89:3367–71.
21. Pollak M. Insulin-like growth factors and prostate cancer. *Epidemiol Rev* 2001;23:59–66.
22. Makridakis NM, Reichardt JK. Molecular epidemiology of hormone-metabolic loci in prostate cancer. *Epidemiol Rev* 2001;23:24–9.
23. Hsing AW. Hormones and prostate cancer: what's next? *Epidemiol Rev* 2001;23:42–58.
24. Zhou A, Hassel BA, Silverman RH. Expression cloning of 2-5A-dependent RNase: a uniquely regulated mediator of interferon action. *Cell* 1993;72:753–65.
25. Castelli J, Wood KA, Youle RJ. The 2-5A system in viral infection and apoptosis. *Biomed Pharmacother* 1998;52:386–90.
26. Hassel BA, Zhou A, Sotomayor C, Maran A, Silverman RH. A dominant negative mutant of 2-5A-dependent RNase suppresses antiproliferative and antiviral effects of interferon. *EMBO J* 1993;12:3297–304.
27. Zhou A, Paranjape J, Brown TL, et al. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *EMBO J* 1997;16:6355–63.
28. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. *Nat Genet* 2002;30:181–4.
29. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. *Am J Hum Genet* 2002;70:1299–304.
30. Rennett H, Bercovich D, Hubert A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. *Am J Hum Genet* 2002;71:981–4.
31. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg⁴⁶²Gln variant is implicated in up to 13% of prostate cancer cases. *Nat Genet* 2002;32:581–3.
32. Xiang Y, Wang Z, Murakami J, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. *Cancer Res* 2003;63:6795–801.
33. Wang L, McDonnell SK, Elkins DA, et al. Analysis of the RNASEL gene in familial and sporadic prostate cancer. *Am J Hum Genet* 2002;71:116–23.
34. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. *Br J Cancer* 2003;89:691–6.
35. Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. *Clin Cancer Res* 2004;10:7150–6.
36. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005;21:263–5.
37. Greenland S, Robins JM. Conceptual problems in the definition and interpretation of attributable fractions. *Am J Epidemiol* 1988;128:1185–97.
38. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the human genome. *Science* 2002;296:2225–9.
39. Maier C, Haessler J, Herkommer K, et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. *Br J Cancer* 2005;92:1159–64.
40. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. *PLoS Pathog* 2006;2:e25.

Appendices – cont.

C: Chronic Disease Epidemiology Class Proposal

PRMD 6636: Chronic Disease Epidemiology
Spring Semester 2007

A Proposal for:

A Life-Course Analytical Approach for Understanding Early Exposure to Androgens and Risk for Prostate Cancer: A Case-Control Study in a Multiethnic Cohort from South Texas

Kathleen C. Torkko, PhD, MSPH, MS

AIMS & HYPOTHESES

Prostate cancer is a disease that is influenced by levels of androgen. Although not conclusively proven, the androgens testosterone and the more bioactive form dihydrotestosterone are thought to be important in the development and growth of prostate tumors. A life-course approach may help improve the understanding of the relationship between androgens and prostate cancer risk given that: 1) prostate tumors may develop a decade or two before the cancer becomes clinically evident, and 2) androgen exposure earlier in life may be more relevant to disease development and growth than androgen levels measured later in life. The goal of this project is to measure surrogates of early and continuing androgen exposure in an existing case-control study and to determine if these exposures are related to risk for prostate cancer. This study will use men enrolled in the SABOR (San Antonio Biomarkers of Risk for Prostate Cancer) study run out of the University of Texas Health Sciences Center, San Antonio. The SABOR study enrolled cohorts of men with and without prostate cancer from south Texas. The control group is undergoing annual screenings for prostate cancer and the study includes White Non-Hispanic, White Hispanic, and African American men.

AIM 1: Develop and test a questionnaire to assess physical events associated with timing of puberty and hair development, loss, and pattern of hair loss. A Medline search will be used to identify existing survey instruments. Authors will be contacted for access to instruments. A questionnaire will be designed and tested in a sample of the SABOR population. The final instrument will be translated into Spanish.

AIM 2: Using the questionnaire developed in AIM 1, information on early androgen exposure will be collected from in men in enrolled in the SABOR study. To ensure higher participation, multiple mailings will be done and will also be administered to non-responding men appearing for their annual study visits.

Hypothesis 2A: Men with prostate cancer will have earlier puberty, earlier hair loss, and vertex patterns of hair loss compared to men without cancer.

Hypothesis 2B: This effect will be stronger in African American men and White Hispanic men.

Hypothesis 2C: In men with prostate cancer, those with later onset of puberty, balding, and a more frontal pattern of balding will have higher grade disease compared to those with earlier onset.

BACKGROUND & SIGNIFICANCE

Prostate cancer is the most commonly diagnosed non-skin cancer and one of the ten leading causes of death in American men.¹ The American Cancer Society estimates that over 218,000 new cases will be diagnosed this year with 27,050 men dying from the disease making it the second leading cause of

death from cancer after lung.² Age and race/ethnicity and remain the two strongest risk factors for prostate cancer. In 1999-2003, the median age of diagnosis was 683 and the more current estimate of prostate cancer incidence is 924.6 (per 100,000) in men 65 and over and 58.5 in men under 65; the rate is 0.7 in men 30-39.⁴ The incidence for prostate cancer is much higher in African Americans (255.5) compared to White Non-Hispanic men (166.6) and all other racial/ethnic groups. African Americans are also at increased risk for dying compared to Whites (mortality rate 62.3 and 21.7, respectively).

The etiology of prostate cancer is not well known, although both genetic and environmental factors are believed to play a role. A twin study from Scandinavia estimated that 42% of the risk for prostate cancer might be explained by heritable factors.⁵ A diverse range of foods and nutrients have been found to moderately affect risk for prostate cancer, including soy, isoflavones, milk, saturated fats, and tomato products.⁶ Higher birth weight and length may be associated with more aggressive disease.⁷ Higher BMI and adult weight gain increase risk of dying from prostate cancer⁸ and aggressive disease is associated with being overweight.^{9,10} Interestingly, obesity itself is inversely related to risk for prostate cancer in middle-aged men.¹¹ A history of diabetes may be associated with a decreased risk of prostate cancer, especially late stage tumors.¹² Many other environmental factors have been studied such as pesticide exposure and red meat consumption, but results have been mixed.

Although prostate cancer diagnosis is strongly associated with increasing age, the initiation of prostate cancer appears to start earlier in adulthood. An autopsy study in 249 men aged 20-69 who died of other causes found evidence of prostate cancer in 2% and 29% percent of prostates from men aged 20-29 and 30-39, respectively.¹³ Given, as discussed earlier, that diagnosis of prostate cancer occurs a decade or more later, this argues for a life-course approach to studying exposures associated with risk for the disease.

Prostate cancer is considered a hormone-dependent malignancy that grows from androgen-dependent tissue. The androgen testosterone and its bioactive form, dihydrotestosterone (DHT), have been shown to be necessary for the normal growth and development of the prostate, and epidemiologic evidence implicates their role in the etiology of prostate cancer.^{14,15,16,15,17} Androgens are involved in controlling the growth of androgen-sensitive malignant prostate cells and levels of estrogen may influence their transformation to a malignant phenotype.¹⁸ The Prostate Cancer Prevention Trial demonstrated that men given the a drug that blocks the metabolism of testosterone had a 24.8% reduction in cancer prevalence over seven years compared to men given placebo.¹⁹

Epidemiologic studies have failed to consistently show that circulating androgens are associated with prostate cancer risk. At least one prospective study has found an association with higher levels of serum testosterone and increased prostate cancer risk.²⁰ In Caucasians, prostate cancer was associated with the ratio of total testosterone to total estradiol, but not to absolute levels of the sex hormones.²¹ Animal studies have shown that androgens are strong tumor promoters for carcinogenesis even at very low concentrations.²² This might explain why it has been difficult to prove associations of elevated serum testosterone levels with risk for prostate cancer. It might also be that early and long-term androgen exposure may have more impact on prostate cancer growth and that blood measurements later in life may be affected by age confounding.²³ This observation again supports a life-course approach to the study of androgen exposure and risk for prostate cancer.

It is the aim of this study to assess surrogate measures of early and continuing androgen exposure and determine how these are related to risk of prostate cancer in a group of White Non-Hispanic, White Hispanic, and African American men from south Texas participating in a mixed cohort/case-control study of prostate cancer. Because androgens play an important role in both puberty²⁴ and hair growth and loss^{25,26}, a questionnaire will be used to assess timing of different exposures including age at shaving initiation, age of hair loss initiation, and hair loss pattern (i.e., frontal vs. vertex). Serum free testosterone levels are strongly associated with baldness.²⁷ Male pattern baldness that often occurs decades before a prostate cancer diagnosis was found to be a risk factor for clinical prostate cancer.²⁸ Vertex balding is associated both with prostate cancer (OR=1.54; 1.19, 2.00; no association found with frontal balding) and with high grade cancer (in men 60-69: OR=2.91; 1.59, 5.32).²⁹ The odds ratio for frontal balding and high grade cancer was 1.80 (1.02, 3.16). A large Kaiser Permanente study found that younger age at

shaving initiation (<14 years old) was associated with a modest risk for prostate cancer (OR=1.49; 95%CI: 1.01,2.22), but only in non-white men.³⁰ The main hypothesis of this study is that men with prostate cancer will have earlier puberty, earlier hair loss, and vertex patterns of hair loss compared to men without cancer and that this relationship will differ by racial/ethnic group.

A secondary hypothesis involves an interesting conundrum in the story of androgens and prostate cancer. Although higher levels of testosterone may be associated with increased risk for prostate cancer, low levels appear to be associated with more aggressive prostate cancer. Men with low total testosterone were more likely to have positive surgical margins on their radical prostatectomy specimens³¹ and more advanced pathological stage or aggressive disease.^{32,33} Two recent Japanese studies demonstrated that low testosterone is associated with higher Gleason grade.^{34,35} Therefore, we hypothesize that in men who have prostate cancer, those with later onset of puberty, balding, and a more frontal pattern of balding will have higher grade disease compared to those with earlier onset.

MATERIALS AND METHODS

Study Design. The proposed study will use a cross-sectional study design in an existing cohort/case-control study on prostate cancer. A questionnaire will be developed to assess early androgen exposures in a selection of prostate cancer cases and controls.

Study Population. Study participants will come from the population-based prospective SABOR cohort study (San Antonio Biomarkers Of Risk for prostate cancer) and its sister study that enrolls existing prostate cancer cases from the same clinics that enroll SABOR patients. Both studies are run through the University of Texas Health Sciences Center, San Antonio (UTHSCSA).³⁶ SABOR began enrolling men in May 2001 to examine differences in risk for prostate cancer by race/ethnicity. To date, approximately 3,000 men have enrolled in the studies. Three racial/ethnic groups reflecting the diversity of the southern Texas population are enrolled: non-Hispanic Whites (NHW), Hispanic Whites (HW), and African Americans (AA). Race is self-identified and Hispanic ethnicity is assigned using the Hazuda model for the identification of Mexican Americans and other Hispanic ethnicities.³⁷ The Hispanic population of south Texas is approximately 95% Mexican American. Table 1 gives numbers of cases and controls by race/ethnicity. All appropriate approvals for the consent form and survey instrument will be sought according to UTHSCSA IRB rules and regulations.

Table 1. Current number so participants in the SABOR studies (as of 3/31/07)

Race/Ethnicity	Total*	Cancer
Non-Hispanic White	1,578	495
Hispanic White	1,052	180
African American	471	69

* Not all men without cancer will be eligible to be controls due to high PSA or abnormal DRE exam

All men with prostate cancer will be eligible to participate. Cases in this analysis will have histologically-confirmed prostate cancer. Gleason scores will be determined from chart reviews and physician reports. High-grade cancers will defined as men with Gleason scores of seven or greater. Prostatectomy scoring will be used preferentially over biopsy scores when available.

Controls, selected from the SABOR cohort, will be eligible for this analysis if they have prostate-specific antigen (PSA) values less than 2.5 ng/ml at all visits (up to six annual visits) and a normal digital rectal exam (DRE) at all visits. Age in the study will be defined as age at diagnosis for the cases and age at last study visit for the controls. Controls will be selected to match cases on age in 5-year age groups.

Questionnaire. Authors with published papers on questionnaires that survey baldness³⁸, and measures of puberty (*e.g.*, age a shaving initiation, age of pubic and/or chest hair appearance)³⁰ will be contacted for access to established and validated instruments. Questions will be edited to meet the needs

of the proposed study and to address study hypotheses. The questionnaire will be tested in a small group of SABOR participants who are not eligible to participate in the proposed study (*i.e.*, abnormal DRE exam with no subsequent cancer diagnosis). Questions will be modified as necessary. The final questionnaire will be translated in to Spanish and both the English and Spanish versions will be sent to the UTHSCSA IRB office for approval. The survey will be mailed at least twice to eligible SABOR participants. Men who attend annual study visits and who have not yet returned a questionnaire will be given the opportunity to complete the questionnaire during their visit. Data will be cleaned and verified by a duplicate entry process.

Amount and type of baldness will be assessed using the Norwood-Hamilton Baldness Scale (Figure 1).³⁹ Men will indicate the pattern that most closely matches their current level and type of baldness and also at what age they first noticed hair loss. Although it is recommended that male balding patterns be assessed by trained personnel, men's self-assessment both currently and retrospectively can be adequate.⁴⁰ For analytic purposes, subjects will be grouped according to the degree and pattern of baldness as: no baldness (Type I), frontal baldness (Types II & III), and vertex baldness (Types III Vertex, IV-VII). To validate this approach, a research nurse will independently assess participants during their next annual visit to determine agreement between self-assessment by the participant and assessment by trained study personnel. The baldness groups may be dichotomized by pattern only as normal/ frontal (Types I-III) versus vertex pattern (Types III Vertex, IV-VII).




Figure 1. Norwood Hamilton Baldness Scale.

Potential Biases. A potential pitfall of the proposed study design is recall bias and exposure misclassification. Men are being asked to remember events that occurred several decades ago. Recall bias may be less of a problem because there is little reason to assume that men with cancer will recall events differently from those without cancer, especially if cases and controls are age-matched. To help men remember ages that balding or shaving started, prompts will be used to help them recall. For example, a man can be asked if he was shaving by the time he entered high school or if he was balding at the time his children were born. Men may be asked to bring pictures to clinic visits showing hair maintenance or loss at various ages.

Statistical Analyses. Other covariates that are collected as part of usual SABOR study activities will be included in the analyses. These include age, height, weight, BMI, and current serum testosterone levels.

An additive scale of early androgen exposures will be tested. For example, balding pattern can be scored as 1 point for vertex pattern and 0 points for none/frontal pattern. For age of hair loss, before age 30 could equal 1 point and >30 = 0 points. For shaving initiation, before age 14 equals 1 point and after age 14 equals 0 points. This score will be tested in the logistic model. If a score is validated, this will become the main variable of interest in the logistic model.

All analyses will be stratified by ethnicity. Univariate associations with prostate cancer will be tested using ANOVA or t-tests (or equivalent non-parametric tests), chi-square tests, and logistic regression analyses. Variables that have a p value <0.1 will be tested in the full logistic model. P-values <0.05 will be considered statistically significant. Analyses will be completed using SAS 9.1 statistical software (SAS institute, Inc., Cary, NC).

Timeline: It is proposed that the study will take two years to complete. Design and development of the survey instrument should occur in the first 6 months, including validation, Spanish translation and IRB approval. Survey mailings and administration will occur during the next 12-15 months (to allow for follow-up and measurements during annual study visits). Data entry, cleaning, and preliminary analysis can begin during this period. Final data cleaning, analysis and paper preparation can be done in the last 3-6 months of the 2-year grant.

REFERENCES

1. **Chan JM, Jou RM, Carroll PR.** The relative impact and future burden of prostate cancer in the United States. *J Urol* 2004;172:S13-S16.
2. **Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.** Cancer statistics, 2007. *CA Cancer J Clin* 2007;57:43-66.
3. **Hayat MJ, Howlader N, Reichman ME, Edwards BK.** Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. *Oncologist* 2007;12:20-37.
4. **Reis LAG, Melbert D, Krapto M, Mariotto A, Miller BA, Feuer EJ, Clegg L, Horner MJ, Howlader N, Eisner MP, Reichman M, Edwards BK.** SEER Cancer Statistics Review, 1975-2004. *National Cancer Institute. Bethesda, MD* 2007; http://seer.cancer.gov/csr/1975_2004/.
5. **Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K.** Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. *N Engl J Med* 2000;343:78-85.
6. **Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B.** Human prostate cancer risk factors. *Cancer* 2004;101:2371-2490.
7. **Nilsen TI, Romundstad PR, Troisi R, Vatten LJ.** Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway. *Int J Cancer* 2005;113:1002-1004.
8. **Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Leitzmann MF.** Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. *Cancer* 2007;109:675-684.
9. **Littman AJ, White E, Kristal AR.** Anthropometrics and Prostate Cancer Risk. *Am J Epidemiol* 2007;:
10. **Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ.** Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. *Cancer Epidemiol Biomarkers Prev* 2001;10:345-353.
11. **Porter MP, Stanford JL.** Obesity and the risk of prostate cancer. *Prostate* 2005;62:316-321.
12. **Zhu K, Lee IM, Sesso HD, Buring JE, Levine RS, Gaziano JM.** History of diabetes mellitus and risk of prostate cancer in physicians. *Am J Epidemiol* 2004;159:978-982.
13. **Sakr WA, Grignon DJ, Crissman JD, Heilbrun LK, Cassin BJ, Pontes JJ, Haas GP.** High grade prostatic intraepithelial neoplasia (HGPIN) and prostatic adenocarcinoma between the ages of 20-69: an autopsy study of 249 cases. *In Vivo* 1994;8:439-443.
14. **Shaneyfelt T, Husein R, Bubley G, Mantzoros CS.** Hormonal predictors of prostate cancer: a meta-analysis. *J Clin Oncol* 2000;18:847-853.
15. **Taplin ME, Ho SM.** Clinical review 134: The endocrinology of prostate cancer. *J Clin Endocrinol Metab* 2001;86:3467-3477.
16. **Debes JD, Tindall DJ.** The role of androgens and the androgen receptor in prostate cancer. *Cancer Lett* 2002;187:1-7.
17. **Hsing AW, Reichardt JKV, Stanczyk FZ.** Hormones and prostate cancer: current perspectives and future directions. *Prostate* 2002;52:213-235.

18. **Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y, Pulkka A, Kurkela R, Herrala A, Kaija H, Isomaa V, Vihko P.** Sex steroid hormone metabolism and prostate cancer. *J Steroid Biochem Mol Biol* 2004;92:281-286.
19. **Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA, Jr.** The influence of finasteride on the development of prostate cancer. *N Engl J Med* 2003;349:215-224.
20. **Parsons JK, Carter HB, Platz EA, Wright EJ, Landis P, Metter EJ.** Serum testosterone and the risk of prostate cancer: potential implications for testosterone therapy. *Cancer Epidemiol Biomarkers Prev* 2005;14:2257-2260.
21. **Tsai CJ, Cohn BA, Cirillo PM, Feldman D, Stanczyk FZ, Whittemore AS.** Sex steroid hormones in young manhood and the risk of subsequent prostate cancer: a longitudinal study in African-Americans and Caucasians (United States). *Cancer Causes Control* 2006;17:1237-1244.
22. **Bosland MC.** Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. *Ann N Y Acad Sci* 2006;1089:168-176.
23. **Zhuang TN, Ly LP, Cumming RG, Handelsman DJ.** Growth and development during early manhood as determinants of prostate size in later life. *J Clin Endocrinol Metab* 2005;90:6055-6063.
24. **Hiort O.** Androgens and puberty. *Best Pract Res Clin Endocrinol Metab* 2002;16:31-41.
25. **Kaufman KD.** Androgens and alopecia. *Mol Cell Endocrinol* 2002;198:89-95.
26. **Hibberts NA, Howell AE, Randall VA.** Balding hair follicle dermal papilla cells contain higher levels of androgen receptors than those from non-balding scalp. *J Endocrinol* 1998;156:59-65.
27. **Demark-Wahnefried W, Lesko SM, Conaway MR, Robertson CN, Clark RV, Lobaugh B, Mathias BJ, Strigo TS, Paulson DF.** Serum androgens: associations with prostate cancer risk and hair patterning. *J Androl* 1997;18:495-500.
28. **Hawk E, Breslow RA, Graubard BI.** Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey. *Cancer Epidemiol Biomarkers Prev* 2000;9:523-527.
29. **Giles GG, Severi G, Sinclair R, English DR, McCredie MR, Johnson W, Boyle P, Hopper JL.** Androgenetic alopecia and prostate cancer: findings from an Australian case-control study. *Cancer Epidemiol Biomarkers Prev* 2002;11:549-553.
30. **Habel LA, Van Den Eeden SK, Friedman GD.** Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. *Prostate* 2000;43:136-143.
31. **Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM.** Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer. *J Urol* 2005;174:2178-2180.
32. **Isom-Batz G, Bianco FJ, Jr., Kattan MW, Mulhall JP, Lilja H, Eastham JA.** Testosterone as a predictor of pathological stage in clinically localized prostate cancer. *J Urol* 2005;173:1935-1937.
33. **Severi G, Morris HA, MacInnis RJ, English DR, Tilley W, Hopper JL, Boyle P, Giles GG.** Circulating steroid hormones and the risk of prostate cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:86-91.
34. **Nishiyama T, Ikarashi T, Hashimoto Y, Suzuki K, Takahashi K.** Association between the dihydrotestosterone level in the prostate and prostate cancer aggressiveness using the Gleason score. *J Urol* 2006;176:1387-1391.
35. **Sekine Y, Ito K, Yamamoto T, Nakazato H, Shibata Y, Hatori M, Suzuki K.** Pretreatment total testosterone levels in patients with prostate cancer in the past two decades in Japan. *Cancer Detect Prev* 2007;.:
36. **Thompson IM, Leach R, Troyer D, Pollock B, Naylor S, Higgins B.** Relationship of body mass index and prostate specific antigen in a population-based study. *Urol Oncol* 2004;22:127-131.
37. **Hazuda HP, Comeaux PJ, Stern MP, Haffner SM, Eifler CW, Rosenthal M.** A comparison of three indicators for identifying Mexican Americans in epidemiologic research. *Am J Epidemiol* 1986;123:96-112.
38. **Ellis JA, Stebbing M, Harrap SB.** Male pattern baldness is not associated with established cardiovascular risk factors in the general population. *Clin Sci (Lond)* 2001;100:401-404.
39. **Norwood OT.** Male pattern baldness: classification and incidence. *South Med J* 1975;68:1359-1365.
40. **Taylor R, Matassa J, Leavy JE, Fritschi L.** Validity of self reported male balding patterns in epidemiological studies. *BMC Public Health* 2004;4:60.:60-

Appendices – cont.

D: Transcript

University of Colorado Health Sciences Center

[Student Admissions and Records](#)

(303) 315-7676 *voice*

(303) 315-3358 *fax*

EPORT DATE: 03/27/2008

KATHLEEN CARROLL TORKKO

YOUR STUDENT NUMBER: XXX-XX-5050

```
=====
      COURSE TITLE          CRSE NR          HRS GRADE          PNTS
=====
----- SPRING SEM 2007    UCDHSC - HEALTH SCIENCES    -----
      NON-DEGREE                      NONDEGREE PUBLIC HEALTH
      CHRNIC DISEASE EPIDEMLGY PRMD 6636          2.0  A          8.0
ATT  2.0  EARNED  2.0  GPAHRS  2.0  GPAPTS  8.00  GPA 4.000
----- FALL SEM 2007      UCDHSC - HEALTH SCIENCES    -----
      NON-DEGREE                      NONDEGREE PUBLIC HEALTH
      ANALYTIC METHODS IN EPI  PRMD 7915          1.0  A          4.0
ATT  1.0  EARNED  1.0  GPAHRS  1.0  GPAPTS  4.00  GPA 4.000
-----
                        CUMULATIVE CREDITS:
      TR HRS  CU HRS  TOT HRS  QUAL HRS  QUAL PTS  GPA
GNON  SEM    0.0    3.0    3.0    3.0    12.00  4.000
*** END OF ACADEMIC RECORD ***
```

Appendices – cont.

E: HSBC 4001/5001 Introduction to Epidemiology Syllabus, Spring 2008



UNIVERSITY OF COLORADO AT DENVER AND HEALTH SCIENCES CENTER COLLEGE OF LIBERAL ARTS & SCIENCES

HBSC 4001 / 5001: INTRODUCTION TO EPIDEMIOLOGY

Term: Spring 2008

Course dates/times: Tuesdays, 4-6:50 p.m.

Course location: (WC)159

Office Hours: By appointment 1 hour before class
Administration Building 255B

Professor: Kathleen C. Torkko, PhD, MSPH

Office location: Anschutz Medical Campus;
RC1-North, Room P18-5120

Phone: 303-724-3063

Email address: kathleen.torkko@uchsc.edu

Web site and/or BlackBoard site

Catalogue Description (HBSC 5001):

Introduces the basic concepts of public health and epidemiology, including assessment of disease in the community, the study of causation and association of disease with lifestyle and environmental risk factors, as well as related special topics. Prereq: upper division standing and course in basic statistical methods. Cross-listed with HBSC 4001.

Instructor Description:

This is an introductory epidemiology course designed for graduate students in the Health and Behavioral Sciences (HBS) program at the University of Colorado Denver. The model for this course is the Introduction to Epidemiology (PRMD 6630) taught in the Department of Preventive Medicine and Biometrics (PMD) at the Health Sciences Center campus. This course will cover the same basic epidemiologic concepts taught in that class allowing students to take advanced epidemiology courses taught through PMD. Because epidemiology is considered part of the medical sciences and its roots come from the study of infectious disease, it is necessary to discuss the medical aspects of disease to illustrate many epidemiologic principles. It will also be necessary for students to brush up on their basic math skills. Content for this course will include some emphasis on topics that may be of more interests to HBS students as compared to the more purely medical focus of the 6630 course.

This course will provide students with an understanding of the basic methods and tools used by epidemiologists to study rates and risks for disease and other factors that affect the health of people. Epidemiologic techniques are used to study a wide variety of health concerns including infectious disease outbreaks, risk factors for chronic diseases, and societal and behavioral factors affecting access to and use of health services. This variety makes epidemiology an exciting and useful area of study. Although this course will not turn you into epidemiologists, I hope you will develop some excitement for the subject and an appreciation for the relevance of epidemiology to your areas of interest.

Epidemiology is not black-and-white. Often there is not necessarily a “right” answer. There may be many ways to study a problem and the choice of an approach will depend on the nature of the questions being asked and on such practicalities as the availability of data and costs. Sometimes we choose the best answer or one way to study a problem, although it is not

necessarily the only answer nor the only way to study it. Epidemiology is often a science of compromises. This can be particularly aggravating for students who might prefer that all questions have either right or wrong answers. All this can make epidemiology a difficult subject to teach and to learn. It is possible that you may pose questions that I am not able to answer immediately, or I may change my mind after further reflection. I also expect that some of you will come up with answers that had not occurred to me. I anticipate a dialog between you and myself. Please feel free to ask questions. I look forward to teaching AND to learning from you.

One theme for this class is the use of epidemiologic techniques to study health disparities in populations. You will be expected to complete a final project consisting of a short paper using what was learned over the semester to describe a health disparity whether by race, gender, age, geography, socioeconomic status or other factors of interest. I have a grant to study health disparities in cancer, particularly in prostate cancer. This is a wonderful opportunity for students to teach the teacher about health disparities, particularly in prostate cancer.

To learn epidemiology, a student may need several passes through the material. It is expected that you will have read all materials and performed all tasks assigned for a particular session prior to the start of class. Reading the material in advance will help you formulate questions. My teaching style will be interactive with in-class exercises and self-assessments to facilitate in-class discussion to help me gauge how well students are learning (and how well I am explaining things!).

Because we are meeting for 3 hours, the class session will be divided into two sub-sessions, A and B, with a short break in between depending on time constraints for a particular lecture. Each session will include two separate lectures on related topics or a lecture with an in-class exercise. Much of the in-class work will require some preparation that will serve as the homework for the (sub-)session.

Handouts of the lecture slides will be posted at least 24 hours prior to each lecture so you may print them for lecture notes. Materials will be accessible on Blackboard. I will be available before each session for questions and additional help. I will try to arrive at least 30-60 minutes prior to each class session (I am a person who is usually running late!). I can make it earlier to class by appointment. Please feel free to e-mail me or call.

Course Objectives:

At the end of this course, the student will:

1. Be able to use epidemiologic terminology
2. Understand and calculate different rates and measures of association (*i.e.*, OR, RR)
3. Articulate clearly the strengths and limitations of different epidemiologic study designs
4. Understand important epidemiologic concepts including confounding, bias, and causation
5. Be able to critically read epidemiologic literature to recognize study design and analytical strengths and limitations.

Required Text:

Gordis L. Epidemiology, 3rd Ed., Elsevier Saunders, 2004

Assignments:

Homework: Generally homework will be assigned for each sub-session. This includes working out problems, providing short answers and definitions, and reading assignments. The homework assigned will usually cover material that will be discussed at the session. Although

this may seem counter-intuitive, grappling with problems and deriving your own solutions before learning how other people have done it will give you experience in solving new problems and allow you to develop a clearer view of the strengths and weaknesses of accepted solutions. Try working out problems first by yourself. If you run into difficulty, feel free to collaborate with your fellow students. But don't just copy answers. If you really don't understand something, discuss it or contact me. Homework must be submitted prior to class electronically or on hard copy at the beginning of class. Failure to do so will deduct 20% from your score (unless you have an EXCELLENT reason for being late). Graded assignments will be returned the next class session. Answers to homework will be posted on Blackboard a week after they are due.

Exams: There will be two formal exams, a midterm (on March 11) and a final (on May 12). The exams will be in-class and open book and will include multiple choice questions and short answers. Some calculations will be required so calculators will be permitted, but not computers. The midterm will cover material presented up to that point; the final will cover the entire term with an emphasis on the latter half. There will be opportunities for formal review before each exam. The first hour of the session will be given to any review questions with the latter 2 hours for the exam.

A final project will entail writing a 3-5 page paper (double-spaced) plus tables or figures. The topic will be of your choice but must cover a health disparity in Colorado, the US, or elsewhere around the world. The topic must be OK'd by me (topic must be chosen by April 1). Preference should be given to cancer, particularly prostate cancer, or another topic that is of great interest to you or your work. There will be no preferential grading given to those who pick prostate cancer, so you are free to choose as you wish. If you can't decide on a topic, I will assign one to you. For this project you will use epidemiology to describe the disparity (rates, risks, etc.) and discuss the types of studies, source of data to describe the disparity. You will briefly discuss any potential problems with the data or gaps in our knowledge. We will discuss the requirements in more detail during a class session. The paper must be submitted electronically or on hard copy by May 6.

Graded midterms will be returned the following class session. Graded final exams and projects will be available at the HBS office after May 19th.

Grades:

Final grades will be determined on a curve and based on homework assignments, in-class exercises, two exams (midterm and final), and a final project according to the following distribution:

Homework	15 %
In-class exercises	15 %
Midterm Exam	25 %
Final Exam	25 %
<u>Final Project</u>	<u>20 %</u>
Total	100%

In-class participation will also be assessed by awarding additional points based on a scale from 0-10 with "0" meaning you never opened your mouth in class to 10 meaning you participated in most if not all discussions. This means a total score of 110 points is possible, but remember, the class is graded on a curve.

Course Policies:

Class attendance and participation is essential for success. No deductions in the final grade will be applied for non-attendance (as long as assignments are turned in on time), but you will miss out on critical questions and discussions. There is no requirement to notify me if you miss class, but I would appreciate a courtesy e-mail to explain unanticipated absences.

The schedule of coursework listed below is not written in stone and may be subject to unplanned changes such as instructor or guest lecturer illness. Additionally, I reserve the right to change the syllabus depending on the needs and interests of the students. Students will be given appropriate, timely, and written notification of any changes.

Homework can either be (clearly) handwritten or typed with room in the margins for me to make comments. Homework can be submitted electronically (MS-Word) or on hard copy. When students' work conveys that they require additional help in composition or math, students will be referred to the Writing Lab and/or the Math Lab. It is your responsibility to clarify missed assignments with me. Homework not submitted in time (by the beginning of the class session) will have a 20% reduction applied to the score. Late homework not submitted by or at the beginning of the following class session will not be graded (although you will get feedback).

If you will miss a scheduled exam, you must notify me prior to the start of the exam. In cases of an emergency, you can call me on my cell phone or contact the HBS office to leave a message. A make-up exam will be re-scheduled. This should be done within a week after the date of the original exam. This may mean you will have to travel to the Anschutz Medical Campus to take the exam unless I can find someone to proctor it on the Auraria Campus. If a make-up is necessary, I ask the other students to refrain from sharing any specific information about the content of the exam with the student(s) who will be taking the make-up.

Course Schedule:

Date	Topic	Required Reading*	Assignments
01/22/08 A	Introduction, Course Requirements		
01/22/08 B	Introduction to Epidemiology	Gordis Chapt 1	None due
01/29/08 A	Measures of Health Status	Gordis Chapt 3 (pp 32-33; 42-46) Chapt 4 (pp 48-58)	Homework 1
01/29/08 B	Incidence & Prevalence	Gordis Chapt 4 (p 48-58)	Homework 2
02/05/08 A	Rate Adjustment & Attributable Risk	Gordis Chapt 4 (pp 58-70) Chapt 12	Homework 3
02/05/08 B	In-class Exercise	Exercise 1	Exercise 1
02/12/08 A	Cohort Studies & Relative Risk	Gordis Chapt 9, Chapt 11 (pp 177-81); <i>Scand J Pub Health</i> 2007;35:306-12.	Homework 4
02/12/08 B	Case-Control Studies & Odds Ratios	Gordis Chapt 10, Chapt 11 (pp 181-88);	Homework 5
02/19/08 A	Other Observational Study Designs / Causation	Gordis Chapt 14	Homework 6
02/19/08 B	In-class Exercise	Exercise 2	Exercise 2

02/26/08 A	Clinical Trials & Prognosis	Gordis Chapt 6, 7, 8	Homework 7
02/26/08 B	In-class Exercise	Exercise 3	Exercise 3
03/04/08 A	Natural History of Disease / Levels of Prevention	Gordis Chapt 2	Homework 8
03/04/08 B	In-class Exercise	Exercise 4	Exercise 4
03/11/08 A	Review questions		
03/11/08 B	MIDTERM EXAM		
03/18/08 A	Bias, Confounding & Effect Modification	Gordis Chapt 15. <i>Scand J Pub Health</i> 2007;35:306	Homework 9
03/18/08 B	In-class Exercise	Exercise 5	Exercise 5
03/25/08	SPRING BREAK – no class		
04/01/08 A	Screening Tests: Sensitivity, Specificity, etc.	Gordis Chapt 5, 18	Homework 10
04/01/08 B	In-class Exercise	Exercise 6	Exercise 6
04/08/08 A	Guest Lecture: Using GIS in Epidemiology - Thomas	<i>Environmental Health Perspectives</i> 2004;112:998-1006	TBA
04/08/08 B	Prostate Cancer Epidemiology; Discussion of Final Health Disparities Project	Cancer 2007;110:1889-99.	Homework 11
04/15/08 A	Guest Lecture: Health Disparities in Tobacco Burden – Levinson	TBA	TBA
04/15/08 B	Epidemiology of Health Disparities	J Transcult Nurs 2008;19:83-91.	Homework 12
04/22/08 A	Guest Lecture: Lifecourse Epidemiology - Dablea	<i>Ann Rev Pub Health</i> 2005;26:1-25	TBA
04/22/08 B	Guest Lecture: Community Epidemiology – Baxter	TBA	TBA
04/29/08 A	Guest Lecture: Sun Protection in Children – Crane	TBA	TBA
04/29/08 B	Criticism of Epidemiology: Hormone Replacement Therapy and Heart Disease in Women	Do We Really Know What Makes Us Healthy? By Gary Taubes, The Times Magazine, 9/16/07	Homework 13
05/06/08 A	Ethics & Human Subject Research	Gordis Chapt 20	Homework 14
05/06/08 B	In-class Exercise	Exercise 7	Exercise 7
05/13/08 A	Review Session		
05/13/08 B	FINAL EXAM		

*Lists for other reading assignments (pertinent papers, etc.) will be available the first day of class or throughout the course before specific classes.

Appendices – cont.

F: List of Panel of Single Nucleotide Polymorphisms

SNP Name	Chromosome	Gene
rs9332975	2	SRD5A2
rs2268794	2	SRD5A2
rs2268796	2	SRD5A2
rs2208532	2	SRD5A2
rs4952222	2	SRD5A2
rs632148	2	SRD5A2
rs3754838	2	SRD5A2
rs9332960	2	SRD5A2
rs12721364	12	VDR
rs9729	12	VDR
rs739837	12	VDR
rs11168267	12	VDR
rs11574077	12	VDR
rs2239182	12	VDR
rs2107301	12	VDR
rs2239179	12	VDR
rs12717991	12	VDR
rs12721370	12	VDR
rs2189480	12	VDR
rs3819545	12	VDR
rs3782905	12	VDR
rs2239186	12	VDR
rs2254210	12	VDR
rs2238136	12	VDR
rs4760648	12	VDR
rs11168287	12	VDR
rs4328262	12	VDR
rs4237855	12	VDR
rs11574026	12	VDR
rs7302235	12	VDR
rs12581281	12	VDR
rs4516035	12	VDR
rs7139166	12	VDR
rs1048691	12	CYP27B1
rs4646537	12	CYP27B1
rs8176345	12	CYP27B1
rs703842	12	CYP27B1
rs4646536	12	CYP27B1
rs2762929	20	CYP24A1
rs8118441	20	CYP24A1
rs6068810	20	CYP24A1
rs6097807	20	CYP24A1
rs2762934	20	CYP24A1
rs1570669	20	CYP24A1
rs2296239	20	CYP24A1

SNP Name	Chromosome	Gene
rs6068816	20	CYP24A1
rs4809958	20	CYP24A1
rs3787554	20	CYP24A1
rs2244719	20	CYP24A1
rs2762941	20	CYP24A1
rs2181874	20	CYP24A1
rs4809960	20	CYP24A1
rs2296241	20	CYP24A1
rs2245153	20	CYP24A1
rs2585428	20	CYP24A1
rs13038432	20	CYP24A1
rs6022999	20	CYP24A1
rs2248359	20	CYP24A1
rs4809957	20	CYP24A1
rs1059519	19	PDF/GDF15
rs1059369	19	PDF/GDF15
rs1804826	19	PDF/GDF15
rs16982345	19	PDF/GDF15
rs1227733	19	PDF/GDF15
rs1491711	4	GC/VDBP
rs17383291	4	GC/VDBP
rs705117	4	GC/VDBP
rs2282679	4	GC/VDBP
rs7041	4	GC/VDBP
rs4752	4	GC/VDBP
rs222020	4	GC/VDBP
rs1352843	4	GC/VDBP
rs3733359	4	GC/VDBP
rs16847028	4	GC/VDBP